The role of biomaterial properties in peri-implant neovascularization by Raines, Andrew Lawrence








of the Requirements for the Degree
Doctor of Philosophy in the
Department of Biomedical Engineering
Georgia Institute of Technology
August, 2011
THE ROLE OF BIOMATERIAL PROPERTIES IN PERI-
IMPLANT NEOVASCULARIZATION
Approved by:
Dr. Barbara D. Boyan, Advisor! ! ! !           Dr. Robert E. Guldberg
Department of Biomedical Engineering! !     School of Mechanical Engineering
Georgia Institute of Technology! ! !         Georgia Institute of Technology
Dr. Zvi Schwartz ! ! ! ! ! ! !   Dr. David J. Mooney
Department of Biomedical Engineering! School of Engineering and Applied Sciences
Georgia Institute of Technology! ! ! ! !      Harvard University
Dr. W. Robert Taylor
School of Medicine
Emory University! ! ! ! !          Date Approved:  April 27, 2011
iii
ACKNOWLEDGEMENTS
! I would first like to thank my advisor, Dr. Barbara D. Boyan for her role in the 
completion of this thesis.  I began working in the Boyan laboratory  in 2004 when I was 
an undergraduate student.  It was Dr. Boyanʼs course that really  sparked my interest in 
research and Dr. Boyan was kind enough to take in a young undergraduate with no 
research experience.  When I completed my  undergraduate degree and decided to 
attend graduate school, Dr. Boyan convinced me to stay  at Georgia Tech and continue 
the project that my undergraduate mentor, Alice Zhao had been working on.  Throughout 
my time as a graduate student, Dr. Boyan has pushed me to understand the science and 
always demanded more from me.  She has also been a strong influence outside of 
research by  listening to what I want to do with my career and providing sound advice. 
She has been very  passionate about my  research and instrumental to me being able to 
get to this point and for that I am deeply  thankful.  I would also like to thank my  co-
advisor, Dr. Zvi Schwartz.  Dr. Schwartz has been very  involved from the beginning in 
the design of my  experiments and the direction in which my research has gone.  He has 
been in the PRL at 5:30 am with me numerous times, performing animal surgeries that 
have been critical in my research.  He also has made me think about what the data 
means and has always expected me to do more.  Both Dr. Boyan and Dr. Schwartz have 
set excellent examples for me with their hard work and dedication and that will help me 
greatly  throughout my  career.  I would also like to thank my thesis committee members. 
Dr. Robert Guldberg has been a great collaborator and I have learned much about how 
to properly  conduct animal research from taking his course.  Drs. W. Robert Taylor and 
David J. Mooney  have provided their time and insight and I am very  appreciative to them 
for that.
iv
! I would also like to thank the past and present members of the Boyan laboratory. 
Without the help I have received from all of them throughout the years, this would not 
have been possible.  I would like to especially  thank the Boyan laboratory  staff: Leang 
Chhun, John Dooley, Crystal Branan, and Sri Vemula have been extremely  helpful in 
culturing cells throughout my  Ph.D.  Reyhaan Chaudhri and Sharon Hyzy  have been 
very  supportive in their roles as laboratory  manager during the last several years.  Dr. 
Rene Olivares-Navarrete, Dr. Yun Wang, and Dr. Hai Yao have been an excellent source 
for knowledge and assistance on various topics.  All of the Boyan laboratory  graduate 
students have made my  time here more enjoyable: Reyhaan Chaudhri, Bryan Bell, 
Ramsey  Kinney, Alice Zhao, Tracy  Denison, Chris Lee, Jiaxuan Chen, Khairat El-
Baradie, Jennifer Hurst-Kennedy, Jamie Lazin, Maya Fisher, Ming Zhong, Tanya 
Farooque, Chris Hermann, Rolando Gittens, Jennie Park, Kathryn Smith, Maryam 
Doroudi, Brandy Rogers, Shirae Leslie, Meredith Myers, Qingfen Pan, Erin Hewitt, 
James Wade.  Ms. Brentis Henderson has been enormously  helpful in tracking down Dr. 
Boyan throughout the years.  I would also like to thank the undergraduate students who 
have worked for me over the years:  James Lee and Nehal Patel were very  helpful in 
providing an extra set of hands for numerous experiments and assays.
! I would also like to thank my  parents for their support during these past 5 years. 
They  may  have asked how much longer until I was finished several times, but they 
always knew  I would get here.  Finally, I would like to acknowledge my  fiance, Crystal 
Branan.  I met her while I was a student and she was a laboratory  technician and the last 
few years with her have been amazing.  Without her love and support, I would certainly 
not be here today and for that I am extremely grateful.
v
TABLE OF CONTENTS
      ACKNOWLEDGEMENTS..........................................................................................iii
      LIST OF TABLES......................................................................................................vii
      LIST OF FIGURES...................................................................................................viii
      SUMMARY...................................................................................................................x
..........................................................................................CHAPTER 1. Introduction! 1
.................................................................................................1.1  Bone Biology! 2
........................................................................................1.2  Neovascularization! 9
.................................................................................................1.3  Biomaterials! 15
...............................................................................1.4  Bone Graft Substitutes! 19
.........................................................................................1.5  Thesis Objective ! 20
....................................................................................................1.6 References! 24
CHAPTER 2:  Regulation of Angiogenesis During Osseointegration by Titanium 
.......................................................................Surface Microstructure and Energy! 34
.................................................................................................2.1  Introduction! 34
...............................................................................2.2  Materials and Methods! 37
.........................................................................................................2.3  Results! 43
...................................................................................................2.4  Discussion! 51
....................................................................................................2.5 References! 60
CHAPTER 3:  Integrin Mediated Signaling Regulates the Angiogenic Response 
....................................................of Osteoblasts to Titanium Substrate Features! 64
..................................................................................................3.1 Introduction! 64





CHAPTER 4.  The Role of VEGF-A in Cell Response to Titanium Surface 
.....................................................................................Microstructure and Energy ! 83
.................................................................................................4.1  Introduction! 83




Chapter 5:  Hyaluronic Acid Stimulates Neovascularization During the 
.....................................................Regeneration of Bone Marrow After Ablation! 121
................................................................................................5.1 Introduction! 121




.......................................................................................CHAPTER 6.  Discussion! 149
................6.1 Role of Ti surface features in promoting neovascularization! 149
...................6.2 Integrin signaling in angiogenic growth factor production! 151
..........................................................................................6.3 Role of VEGF-A! 153





2-1:  Bone to implant contact at the cortical bone – implant interface!          51
4-1: % reduction in VEGF-A protein levels in shRNA transduced MG63 cells!          96
4-2: % reduction in VEGF-A gene expression in shRNA transduced MG63 cells!          96
5-1: Materials injected into the medullary canal following marrow ablation!        127
A-1:  Characterization of Ti surface roughness!        158
A-2: Characterization of surface chemical composition!        158
viii
LIST OF FIGURES
1-1: Schematic illustrating the hierarchial structure of bone                                              4
1-2: Schematic illustrating bone resorption and new bone formation!            5
1-3: Schematic illustrating MSC differentiation to osteoblasts!            6
1-4: Schematic illustrating the process of angiogenesis!          12
2-1: MG63 cell response to Ti substrates!          45
2-2: Angiogenic growth factor production by MG63!          46
2-3: HOB cell response to Ti substrates!          47
2-4: Effect of Vitamin D treatment on angiogenic growth factors!          49
2-5: Endothelial cell differentiation!          53
2-6: Endothelial cell tubule formation!          54
2-7: Establishment of Ti in vivo model!          55
2-8: Histology images for Ti implants!          56
2-9: Bone to implant contact and neovascularization in vivo!          57
3-1: Integrin α1 silencing!          71
3-2: Integrin α2 silencing!          74
3-3: Integrin α5 silencing!          75
3-4:  Integrin β1 silencing!          76
4-1:  MG63 cell response to Flk-1 antibody treatment!          94
4-2:  MG63 angiogenic growth factor production Flk-1 antibody treatment!          95
4-3: Verification of VEGF-A silencing in MG63 cells !          99
4-4: siVEGF-A cell response to Ti surfaces!        100
4-5: siVEGF-A angiogenic growth factor production!        101
ix
4-6: siVEGF-A endothelial cell tubule formation!        103
4-7:  rhVEGF-A treatment of MG63 and siVEGF-A MG63 cells!        104
4-8: rhVEGF-A treatment of MG63 and siVEGF-A MG63 cells!        107
4-9: rhVEGF-A treatment of MG63 and siVEGF-A MG63 cells!        108
4-10: rhFGF-2 treatment of MG63 and siVEGF-A MG63 cells!        109
4-11: rhFGF-2 treatment of MG63 and siVEGF-A MG63 cells!        111
4-12: rhFGF-2 treatment of MG63 and siVEGF-A MG63 cells!        112
5-1: µCT images of ablated tibias!        129
5-2: Timecourse assessment of vascular morphology !        130
5-3: Effect of NaHY + DBM on neovascularization!        132
5-4: Bone volume fraction in NaHY + DBM treated animals!        133
5-5: Corrected vessel volume fraction !        136
5-6:  Representative histology images of NaHY + DBM treated animals!        137
5-7: Histology blood vessel number!        138
5-8: Timecourse assessment of vascular morphology in old animals!        139
5-9: Bone volume fraction in old animals!        140
A-1: SEM images of PT and SLA Ti surfaces!        158
A-2: Vessel volume fraction in contralateral control limbs!        159
A-3: Vessel volume fraction in contralateral control limbs!        160
A-4: Vessel volume fraction in contralateral control limbs!        161
x
SUMMARY
! An understanding of the interactions between orthopaedic and dental implant 
surfaces with the surrounding host tissue is critical in the design of next generation 
implants to improve osseointegration and clinical success rates.  Critical to the process 
of osseointegration is the rapid establishment of a patent neovasculature in the peri-
implant space to allow for the delivery  of oxygen, nutrients, and progenitor cells.  The 
central aim of this thesis is to understand how biomaterials regulate cellular and host 
tissue response to elicit a pro-angiogenic microenvironment at the implant/tissue 
interface.  To address this question, the studies performed in this thesis aim to 1) 
determine whether biomaterial surface properties can modulate the production and 
secretion of pro-angiogenic growth factors by  cells, 2) determine the role of integrin and 
VEGF-A signaling in the angiogenic response of cells to implant surface features, and 3) 
to determine whether neovascularization in response to an implanted biomaterial can be 
modulated in vivo.  The results demonstrate that biomaterial surface microtopography 
and surface energy  can increase the production of pro-angiogenic growth factors by 
osteoblasts and that these growth factors stimulate the differentiation of endothelial cells 
in a paracrine manner and the results suggest that signaling through specific integrin 
receptors affects the production of angiogenic growth factors by  osteoblast-like cells. 
Further, using a novel in vivo model, the results demonstrate that a combination of a 
rough surface microtopography and high surface energy  can improve bone-to-implant 
contact and neovascularization. The results of these studies also suggest that VEGF-A 
produced by  osteoblast-like cells has both an autocrine and paracrine effect.  VEGF-A 
silenced cells exhibited reduced production of both pro-angiogenic and osteogenic 
growth factors in response to surface microtopgraphy  and surface energy, and 
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conditioned media from VEGF-A silenced osteoblast-like cell cultures failed to stimulate 
endothelial cell differentiation in an in vitro model.  Finally, the results show  that by 
combining angiogenic and osteogenic biomaterials, new bone formation and 
neovascularization can be enhanced.  Taken together, this research helps to provide a 
better understanding of the role of material properties in cell and host tissue response 
and will aid in the improvement of the design of new implants.
CHAPTER 1. Introduction
! Musculoskeletal disease is one of the leading causes of long-term pain and 
disability  and affects hundreds of millions of people worldwide [1].  In the United States 
alone, the estimated costs of all musculoskeletal disease in terms of medical bills and 
lost wages is $849 billion annually  [2].  With an increasingly  aging population this 
number is expected to grow significantly  over the next several decades [3].  Implants in 
the fields of orthopaedics and dentistry  aim to relieve pain and restore the function of 
joints and damaged or diseased tissue.  The goal of any implant in orthopaedics or 
dentistry  is osseointegration of the implant with the surrounding host tissue.  In young 
patients or in sites of healthy  bone, the success rates of orthopaedic and dental implants 
can be as high as 95%  [4, 5].  However, in sites of poor bone quality, either due to 
disease or other factors such as smoking, the overall clinical success of implants drops 
significantly  [6, 7], highlighting the need for better designed implants to promote 
osseointegration and ultimately  improve implant success. Critical to the process of 
implant osseointegration is the establishment of a patent vascular supply  at the implant/
tissue interface to allow for the delivery  of oxygen, nutrients, and progenitor cells to the 
injury site.  
! The studies presented in this thesis aim to 1) determine whether biomaterial 
surface properties can modulate the production and secretion of pro-angiogenic growth 
factors by cells, 2) determine the role of integrin and VEGF-A signaling in the angiogenic 
response of cells to implant surface features, and 3) to determine whether 
neovascularization in response to an implanted biomaterial can be modulated in vivo. 
The remainder of this chapter will discuss the relevant background material that serves 
as a basis for the aims of this thesis.  These topics include a discussion of general bone 
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biology and the process of neovascularization.  Next, there will be a discussion of the 
properties and use of titanium (Ti) as a biomaterial and host cellular and tissue response 
to titanium implants.  There will also be a section concerning bone graft substitutes and 
their use in orthopaedic applications.  Finally, the overall objective of this thesis will be 
outlined with regard to the highlighted clinical and scientific needs.
1.1  Bone Biology
1.1.1 Bone Structure
! Bone is one of the hardest tissues in the human body. It is a dynamic tissue that 
provides structural support and protection to internal organs as well as metabolic and 
physiological functions for the body.  Bone is also the strongest tissue in the human body 
with tensile strengths of up to 130 MPa and compressive strengths of up  to 190 MPa [8]. 
Despite its strong mechanical properties, the density of human bone ranges from 0.30 g/
cm3 to 1.85 g/cm3, making bone a highly  efficient structure [9].  From a metabolic and 
physiological perspective, bone serves as a source for calcium and phosphorus in the 
body, which, when released during bone resorption, helps to maintain overall mineral ion 
homeostasis.  In general, bone can be classified into two types within the body, cortical 
bone and trabecular bone.
! Cortical bone, also known as compact bone, comprises the outer layer of all 
bones and the diaphysis of long bones [10]. The modulus of cortical bone is 
approximately  17,000 MPa [11].  Cortical bone is composed of distinct units, termed 
osteons, which consist of vascular channels circumferentially  surrounded by  lamellar 
bone.  The vascular channels located in osteons are called haversian canals and 
typically  consist of cells, blood vessels and sometimes nerves.  The blood vessels within 
haversian canals are capillary-like and are derived from the epiphyseal metaphyseal 
arteries [12].  
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! Trabecular, or cancellous bone, is primarily  found in the metaphysis and 
epiphysis of long bones and in the vertebrae [10].  Trabecular bone is composed of a 
three-dimensional lattice network of bone spicules aligned along areas of stress.  The 
highly  porous structure of trabecular bone results in a much lower density  than that of 
cortical bone and a corresponding lower modulus, with values typically  ranging between 
10 and 2,000 MPa, depending on the location of the bone [11, 13].  Trabecular bone has 
a much larger surface area than does cortical bone and is subject to a much greater rate 
of bone turnover.
! Bone is a composite material, consisting of both organic and inorganic phases. 
The inorganic component of bone is calcium hydroxyapatite [Ca10(PO4)6(OH)2] which 
occurs in the matrix as crystals approximately  20-80 nm in length and 2-5 nm in 
thickness [14].  The organic component of bone is principally  type I collagen, which 
comprises about 90%  of the organic matrix [15].  The remainder of the organic matrix 
contains proteins such as osteocalcin, osteopontin, bone sialoprotein, osteonectin and 
bone proteoglycans [15].  The hierarchical organization of bone from individual collagen 
fibers and hydroxyapatite crystals to lamellar structures and osteons to the macroscopic 
bone is outlined in Figure 1-1.
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Figure 1-1.  Schematic illustrating the hierarchical structure of bone from the whole bone 
to individual collagen molecules and hydroxyapatite crystals [16] 
1.1.2 Bone Remodeling
! As mentioned above, bone is a dynamic tissue that is constantly  remodeled 
throughout life through bone resorption and new bone formation.  Bone is resorbed by 
cells called osteoclasts.  Mature osteoclasts are large, multinucleated cells derived from 
haematopoietic precursors that also give rise to monocytes and macrophages [17]. 
Osteoclasts are identified by  their ability  to produce tartrate-resistant acid phosphatase 
(TRAP) and by their ruffled border which results from infoldings of the cell membrane at 
the bone surface interface.  At sites of bone remodeling, osteoclasts attach to the bone 
surface, lower the pH of the local environment through the generation of hydrogen ions, 
and produce and release matrix metalloproteases and proteolytic enzymes to dissolve 
the hydroxyapatite crystals and remove the organic components of the bone matrix [18].
! New bone is laid down at sites of bone resorption by bone forming cells called 
osteoblasts.  Unlike osteoclasts, osteoblasts are derived from mesenchymal progenitor 
cells [19].  The primary distinctive features of osteoblasts are the ability  to produce type I 
collagen, their responsiveness to parathyroid hormone, and their production of 
osteocalcin in response to the systesmic osteotropic hormone 1α,25-dihydroxyvitamin 
D3.   Osteoblasts are recruited to sites of bone resorption by osteoclasts, where they 
secrete new bone matrix called osteoid.  Osteoid is later mineralized as osteoblasts 
continue to mature.  Osteoblasts that have become embedded within a mineralized 
matrix are called osteocytes.  Osteocytes are the most numerous type of bone cell and 
are terminally  differentiated cells that play  an important role in communication with each 
other and bone cells on the surface through the bone canaliculi.
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Figure 1-2.  Schematic illustrating the basic process of bone resorption and new  bone 
formation [20].
1.1.3 Osteoblast Differentiation and Maturation
! Osteoblasts and osteocytes are derived from multipotent, mesenchymal 
progenitor stem cells (MSCs) that can give rise to cells of multiple different lineages, 
including bone, cartilage, fat, and muscle [21].  The differentiation of MSCs into the 
various lineages is controlled tightly by  several transcription factors, hormones, and 
growth factors. Runx2 has been identified as the major transcription factor responsible 
for controlling osteoblast differentiation [22]. Upregulation of Runx2, along with 
downregulation of PPARγ and Sox9 pushes MSCs towards an osteoblast lineage. Runx2 
belongs to the Runt family  of transcription factors and is expressed in MSCs at the onset 
of skeletal development and throughout osteoblast differentiation.  Runx regulatory 
elements are found within the major osteoblastic genes, including collagen I, 
osteopontin, bone sialoprotein, and osteocalcin [23].  Numerous other transcription 
factors have been identified that also play a role in the differentiation of progenitor cells 
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into fully  mature osteoblasts.  One of these transcription factors, osterix, is expressed 
specifically  by  osteoblasts and is important for osteoblast differentiation.  Osterix is 
expressed downstream from Runx2, and can form a complex with nuclear factor of 
activated T cells (NFAT) to promote collagen I promoter activity  and Wnt signaling [24]. 
Signaling through the canonical Wnt pathway  has been found to be an important 
signaling pathway  in controlling bone formation and bone mass [25, 26].  Inactivation of 
β-catenin, a downstream member of the canonical Wnt pathway, inhibits osteoblast 
differentiation from mesenchymal progenitor cell populations [27].  
Figure 1-3.  Schematic illustrating the differentiation from mesenchymal progenitor cells 
to osteo-progenitors to fully mature osteoblasts and osteocytes [21]
! The differentiation of MSCs down the osteoblastic lineage is also subject to 
control by  systemic hormones and growth factors.  Parathyroid hormone (PTH) 
promotes osteoblast differentiation through the phosphorylation and activation of Runx2 
[28].  PTH further inhibits Runx2 degradation and promotes osterix while inhibiting 
PPARγ expression [29].  The systemic osteotropic hormone, 1α,25(OH)2D3 also 
upregulates Runx2 expression and downregulates PPARγ, result ing in 
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osteoblastogenesis [30].  Growth factor signaling has also been found to play a role in 
osteoblast differentiation in MSCs.  Bone morphogenetic protein 2 (BMP-2) promotes 
both Runx2 and osterix expression in MSCs [31, 32].  Transforming growth factor β and 
fibroblast growth factor 2 (FGF-2) also promote bone formation by  increasing Runx2 
phosphorylation and activity [33, 34].
! Mesenchymal progenitor cells that differentiate down the osteoblast lineage 
undergo maturation from osteo-progenitor cells to immature osteoblasts and finally to 
mature osteoblasts and osteocytes.  The maturation process of osteoblasts is generally 
marked by three stages: proliferation, matrix secretion, and mineralization [35].  Cells 
express numerous genes and proteins during each of these stages that can be identified 
to determine osteoblast maturation.  During the proliferative stage of osteoblast 
maturation, cells express cell cycle and cell growth related genes, including c-myc, c-fos, 
and AP-1 [36].  During this time, cells also express genes related to osteoblast 
extracellular matrix development.  These genes include type I collagen, fibronectin, and 
TGFβ [37].  Following proliferation, the expression of alkaline phosphatase, an enzyme 
associated with bone cell phenotype, is increased significantly.  Alkaline phosphatase 
levels remain high in osteoblast like cell cultures until the onset of matrix mineralization. 
During matrix mineralization, cells upregulate expression of osteocalcin, osteopontin, 
osteonectin, and other mineralization associated proteins.  There is also an increase in 
calcium associated with mineral deposition in the extracellular matrix.  Understanding 
the temporal sequence of gene expression associated with bone formation allows for the 
ability to determine osteoblast maturation in cell cultures in vitro.
1.1.4 Bone & Blood
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! The importance of blood vessels in the formation of bone was documented as 
early  as the 1700s [38, 39].  The vascular system transports oxygen, nutrients, systemic 
hormones, growth factors, and cells throughout the body.  Bone formation during 
development occurs through two distinct mechanisms:  intramembranous ossification 
and endochondral ossification [40].  Both of these ossification processes occur in close 
proximity  to vascular ingrowth.  During intramembranous ossification, new capillary 
invasion into the mesenchymal zone occurs prior to the differentiation of mesenchymal 
progenitor cells into mature osteoblasts and deposition of mineralized bone spicules 
[41].  During endochondral ossification, vascular invasion into the hypertrophic zone of 
the growth plate is necessary for the longitudinal growth of long bones [42]. 
Hypertrophic chondrocytes are known to secrete several pro-angiogenic growth factors 
and the coupling of chondrogenesis and osteogenesis during bone growth is highly 
dependent on the rate of vascularization of the growth plate [43].  The tight interplay 
between vascularization and bone formation is highlighted by the fact that disruption of 
this process results in a reduction in bone formation and increase in growth plate 
thickness [44].  
! In addition to its importance during development and growth of the skeleton, the 
presence of a blood supply  is also important during bone fracture repair and 
osseointegration.  Bone is a unique tissue in that it has the ability  to repair itself without 
the development of a fibrous scar.  Following injury  to bone, there is a rapid invasion of 
capillary  blood vessels to the injured site from the surrounding vasculature.  This 
capillary  invasion allows for the delivery  of mesenchymal cells to the damaged region 
[45].  The fracture site is stabilized with the formation of a fracture callus, which is 
remodeled to restore the normal vascular supply  and bone structure.  In some cases, 
fractures fail to repair, resulting in non-unions.  There are several reasons for the failure 
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of fractures to heal, including anti-inflammatory  drugs, steroids, calcium deficiencies, and 
the absence of a functional vascular network at the fracture site [46].  The understanding 
that angiogenesis is an important part of bone formation and repair has led to greater 
research into combining angiogenic therapies with osteogenic therapies to promote bone 
formation in tissue engineering.
1.2  Neovascularization
! A vascular network is one of the first organ systems to develop during 
embryogenesis.  Within the developing embryo, the vascular network develops from a 
process called vasculogenesis.  In vasculogenesis, mesodermal cells differentiate into 
hemangioblasts, which are the precursor cells of both haematopoietic and endothelial 
cells.  Hemangioblasts further differentiate into angioblasts that aggregate together to 
form blood islands.  Elongation of these blood islands into cord-like structures forms the 
primary  blood vascular plexus that consists of capillaries formed by  endothelial cells [47]. 
After the development of the primary vascular network and in the adult organism, new 
blood vessel formation occurs primarily through a process called angiogenesis.
1.2.1 Angiogenesis
! Angiogenesis refers to the sprouting and subsequent stabilization of new blood 
vessels from the pre-existing vasculature [48].  Angiogenesis occurs both physiologically 
during vascular growth and remodeling (i.e. during long bone growth) as well as 
pathologically  as during diabetes and tumor growth.  The process of angiogenesis can 
generally  be broken down into four stages that will be described in further detail:  (1) 
activation of endothelial cells in response to an angiogenic stimulus, (2) degradation of 
the basement membrane of the surrounding vasculature, (3) migration of endothelial 
cells in the direction of the angiogenic stimulus, forming the initial capillary  sprout, and 
(4) stabilization and maturation of the newly formed vessel.  
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1.2.1.1 Endothelial cell activation
! Initiation of angiogenesis begins with the activation of endothelial cells in 
response to an angiogenic stimulus.  One of the primary  stimuli for the expansion of the 
vascular bed is hypoxia [48].  Oxygenation of cells within the body occurs via the 
diffusion of oxygen from the surrounding vasculature.   When cells are located beyond 
the diffusion limit of oxygen in the tissue, the cells become hypoxic, resulting in 
activation of the hypoxia inducible factor (HIF) pathway  [49].  Under conditions of normal 
oxygen tension, HIF-1α subunits are hydroxylated and marked for degradation by  the 
proteosome by  the von Hippel-Lindau (VHL) tumor suppressor protein [50].  However, 
when oxygen concentrations drop below approximately  5%, HIF-1α accumulates in the 
cytoplasm and translocates to the nucleus, where it interacts with the constitutively 
expressed HIF-1β subunit to activate gene transcription.  Several genes associated with 
angiogenesis are either directly  or indirectly  affected in response to hypoxia, including 
vascular endothelial growth factor and its receptors, fibroblast growth factors, 
angiopoietins, and matrix metalloproteinases [51-56].  Secretion of these growth factors 
by hypoxic cells leads to the activation of endothelial cells.
1.2.1.2 Basement membrane degradation
! Several growth factors are known to be mitogenic for endothelial cells including 
TGFβ, FGF-2, HGF, IL-8 and the angiopoietins [47].  However, the most widely 
recognized growth factor as being essential for the initiation of angiogenesis is vascular 
endothelial growth factor (VEGF) A.  Endothelial cells express the VEGF receptors 
VEGFR1 (Flt1) and VEGFR2 (Flk1/KDR).  Activation of the VEGF receptors on 
endothelial cells stimulates their growth and prevents apoptosis [57, 58].  VEGF-A has 
also been found to stimulate the production of matrix metalloproteinases (MMPs) in 
endothelial cells [59].  MMPs secreted by endothelial cells in response to VEGF include 
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MMP-1, -2, and -9 [60].  These MMPs degrade the basement membrane consisting of 
collagen IV, laminin, and other components allowing for the migration of endothelial cells 
in the direction of the angiogenic stimulus.
1.2.1.3 Endothelial cell migration
! As mendtioned above, VEGF-A acts to promote endothelial cell growth.  In 
response to an angiogenic stimulus, the endothelial cells that are in the leading position 
are referred to as tip cells [47].  These tip cells sprout filopodia in the direction of the 
VEGF gradient within the tissue and ultimately guide the direction of the growing 
capillary within the tissue [61].
1.2.1.4 Vessel maturation
! After the development of a capillary  sprout in response to an angiogenic 
stimulus, the newly  formed vessel is stabilized by  the recruitment of mural cells.  The 
maturation of blood vessels is regulated by many different growth factors and signaling 
systems.  Platelet derived growth factor (PDGF) B plays a role in recruiting pericytes to 
form walls around newly  formed vessels.  In PDGFB deficient mice, the number of 
pericytes is decreased and blood vessels are dilated and develop microaneurysms, 
resulting in embryonic lethality  [62].  The angiopoietins (Ang-1 and -2) and their receptor 
Tie2 also play  an important role in the maturation of blood vessels.  The Ang-1/Tie2 
signaling cascade lowers vascular permeability  by promoting the association of pericytes 
with the endothelium [63].  Further, in Tie2 knockout mice, the process of capillary 
maturation is disturbed, resulting in embryonic lethality  [64].  Overall, the process of 
angiogenesis is coordinated by  several classes of growth factors and their receptors in 
both endothelial cells and mural cells and each step is tightly  regulated and necessary 
for the successful development of new blood vessels.
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Figure 1-4.  Schematic illustrating the basic mechanism of angiogenesis.  Angiogenic 
stimulants are secreted by cells in response to a change in environmental conditions.  
The basement membrane of the surrounding vasculature is degraded and endothelial 
cells migrate in the direction of the angiogenic stimulus and form a nascent endothelial 
sprout [65].
1.2.2 VEGF
! VEGF-A is an approximately  45 KDa glycoprotein that acts as both a permeability 
and angiogenic growth factor [66, 67].  VEGF-A belongs to a family of associated genes 
that includes VEGF-B, -C, -D, and placental growth factor (PLGF).  While the other 
members of the VEGF family  have been found to control the growth and differentiation of 
the vascular system, VEGF-A is widely  recognized as the key regulator of blood vessel 
growth and development in vivo.  VEGF-A has been demonstrated to stimulate growth, 
prevent apoptosis, and promote the migration of endothelial cells in vitro [68].  The 
human VEGF-A gene is comprised of eight exons and seven introns and can be 
alternatively  spliced to generate four VEGF-A isoforms, VEGF-A121, VEGF-A165, VEGF-
A189, and VEGF-A206 [69, 70].  VEGF-A isoforms 189 and 206 contain all eight exons and 
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are bound to the extracellular matrix (ECM) through a heparin-binding domain.  VEGF-
A121 does not contain exons six or seven and is freely  diffusible within the ECM, while 
VEGF-A165, the most abundant isoform, does not contain exon six and has intermediate 
ECM binding properties [71].  The expression of VEGF-A by cells is regulated by  several 
mechanisms, including oxygen tension and growth factors.  The VEGF-A gene contains 
a hypoxia response element (HRE) and its expression is activated in response to 
activation of the HIF pathway  [72].  Numerous growth factors have also been found to 
stimulate VEGF-A gene expression including TGF-α and -β, insulin-like growth factor, 
FGF, and PDGF [68].  
! VEGF-A binds two receptor tyrosine kinases located on the cell surface, 
VEGFR1 (Flt1) and VEGFR2 (Flk1/KDR).  VEGFR1 was the first receptor to be identified 
for VEGF-A [73].  In response to VEGF-A binding, VEGFR1 undergoes weak tyrosine 
autophosphorylation [73, 74], and it is thought that VEGFR1 is not the primary receptor 
responsible for VEGF-A effects, but rather is a decoy  receptor, allowing for negative 
regulation of VEGF-A on the vascular endothelium [75].  VEGFR2 is recognized as the 
primary  mediator of the mitogenic effects of VEGF-A during neo-vascularization.  Upon 
binding, VEGFR2 dimerizes and undergoes strong autophosphorylation, inducing the 
downstream phosphorylation of multiple proteins in endothelial cells, including 
phospholipase C-γ, PI-3 kinase, Ras, and members of the Src family  [76, 77].  The 
importance of VEGFR2 in neo-vascularization is highlighted by  the fact that VEGFR2 
null mice die in early  embryogenesis due to a failure to develop blood islands and 
organized blood vessels [78].  Further, VEGFR2 but not VEGFR1 is necessary  for the 
anti-apoptotic effects of VEGF-A in human umbilical vein endtothelial cells [58].  
1.2.3 FGF-2
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! Basic fibroblast growth factor (FGF-2) belongs to a large family  of protein growth 
factors that currently  includes 22 members based on the homology  of their amino acid 
sequences [79].  Five isoforms of FGF-2 have been identified that occur through 
alternative splicing of the same gene resulting in protein products with molecular weights 
of 18, 22, 22.5, 24, and 34 KDa [80].  FGF-2 has the capacity  to increase the migrational 
ability  of endothelial and smooth muscle cells [81].  FGF-2 has also been found to 
stimulate the proliferation of endothelial cells and plays a role in the remodeling of the 
extracellular matrix during angiogenesis by  stimulating the proteolysis of ECM 
components [82, 83].  FGF-2 exerts its effects through four structurally  releated proteins 
receptors, FGF receptors (FGFR) 1-4 which contain immunoglobulin-like amino acid 
sequences in their extracellular ligand binding domain [84].  FGF-2 is one of the most 
important growth factors involved in tumor angiogenesis and plays an important role in 
the regulation of physiological angiogenesis in vivo.
1.2.4 Angiopoietin-1
! Angiopoietin-1 (Ang-1) is an approximately  70 KDa glycoprotein that belongs to a 
family  of four proteins (Ang-1, -2, -3, and -4) that are grouped together based on the 
homology  of the amino acid sequences [85].  Ang-1 plays an important role in the later 
stages of angiogenesis through stabilization of the new capillary  sprout.  Inactivation of 
the Ang-1 gene in mice results in a decrease in the number of large vessels, thinning of 
the walls of larger blood vessels, and disintegration of the blood vessel network [64]. 
Ang-1 signaling has been found to promote endothelial cell survival by  promoting the 
expression of the anti-apoptotic protein survivin [86] and acts to recruit pericytes and 
smooth muscle cells in the peri-vascular space to newly  formed endothelial cell sprouts. 




! Biomaterials are generally  divided into four major classes of materials: metals, 
ceramics, polymers, and natural materials [87]. Orthopaedic biomaterials have been very 
successful in restoring mobility  and quality  of life to millions of individuals, and represent 
a large segment of the biomaterials industry.  In 2002, orthopaedic biomaterial sales 
were approximately  $14 billion and the orthopaedic biomaterial market is expected to 
grow at a rate of nearly 10% annually [88].
! Metals and metal alloys are the most commonly  used materials in orthopaedic 
and dental implants because of their tensile strength, stiffness, and resistance to wear 
[89].  Titanium (Ti) and its alloys (Ti6Al4V), stainless steel, and cobalt alloys (CoCrMo) 
are the primary  metals used in orthopaedics [88].  Titanium and Ti6Al4V are commonly 
used in total joint replacements because of their high corrosion resistance compared to 
stainless steel and CoCrMo alloys.  This resistance is due to the formation of a passive 
oxide film (TiO2) that forms on their surface.  Ti and Ti alloys also possess mechanical 
properties closer to those of native bone.  In dental applications, commercially pure Ti 
(cpTi) is predominantly  used because it is more biocompatible than Ti alloys and fatigue 
and wear resistance are not as big of an issue.  Regardless of the material used, all 
biomaterials elicit a host response when implanted in vivo.
1.3.1 Host Response to Biomaterials
! Biocompatibility  is defined as the ability  of a material to perform with an 
appropriate response in a specific application [90].  Upon the implantation of a 
biomaterial into the body, there is generally  a well-defined sequence of events that 
occurs involving inflammation, wound healing, and foreign-body  reaction in response to 
injury.  
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! The first event to occur in response to injury  to vascularized tissue is the 
development of a provisional matrix through the formation of a haematoma at the 
implant site [91].  The provisional matrix consists of fibrin, produced by  activation of 
blood coagulation and contains mitogens, cytokines, and growth factors to initiate and 
control the subsequent wound healing process.   The first inflammatory  cells to come 
into contact with a biomaterial surface are neutrophils [92].  The acute inflammatory 
phase typically  only  lasts the first few days after implantation of a biomaterial and the 
major role of neutrophils during the acute inflammatory  phase is to phagocytose 
microorganisms and foreign materials.
! The formation of granulation tissue occurs as early  as 3-5 days after implantation 
of a biomaterial and can last several weeks [91].  Granulation tissue is characteristic of 
the wound healing response and is a highly  vascularized tissue containing numerous 
small blood vessels formed by  angiogenesis.  Granulation tissue is also characterized by 
proliferating fibroblasts that are active in creating a matrix containing collagens and 
proteglycans [91].  Monocytes and macrophages are also characteristic of granulation 
tissue.
! Materials that have poor biocompatibility elicit a foreign body  reaction where 
foreign body  giant cells and components of the granulation tissue, including fibroblasts 
and macrophages persist at the implant/tissue interface.  The long-term presence of a 
foreign body  reaction leads to fibrous encapsulation of the implanted biomaterial, and 
can lead to implant loosening and ultimately implant failure.
! The goal of any implant in orthopaedics and dentistry  is osseointegration of the 
implant with the surrounding host tissue.  Osseointegration is defined as the direct 
contact of bone to the surface of a biomaterial, without the formation of a fibrous layer 
[93].  During peri-implant healing, new bone is formed as a result of the recruitment and 
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migration of osteogenic cells to the implant surface, resulting in the apparent growth of 
new bone tissue along the implant surface, termed bone-to-implant-contact [94].  The 
degree of bone-to-implant contact can be measured histologically  and is effected by  the 
surface topography and chemistry of the implant [95].  
1.3.2 Cell Response to Ti
! The surface properties of materials contribute to host cellular response and 
ultimately  determine the overall success or failure of an implanted biomaterial.  Cells 
interact with the surface of a material through an adsorbed layer of proteins, ions, 
sugars, and lipids present in the blood and tissue fluid.  The surface properties of 
materials are largely  responsible for this interaction, and the surface properties that 
affect this process include topography, surface energy, chemistry, and surface charge 
[96].  In vitro studies have shown that Ti surface microtopography and energy  can affect 
the selective adsorption of proteins including albumin, fibronectin, and vitronectin onto 
the surface [97, 98].
Osteoblasts interact with their substrate primarily  via integrin binding to 
extracellular matrix (ECM) proteins [99].  Integrins are heterodimeric transmembrane 
glycoprotein receptor complexes consisting of non-covalently  associated α and β 
subunits.  Integrin receptors bind ECM proteins on the outside of the cell and associate 
with the cytoskeleton and signaling complexes inside the cell to transduce signals. 
Osteoblasts express several integrin α and β subunits including α1, α2, α3, α4, α5, α6, αv, 
β1, and β3 [100-102]. The expression of integrin subunits by  osteoblast-like cells is 
regulated by surface chemical composition and topography [103, 104]
Upon binding, integrin molecules cluster into focal adhesions, where they  initiate 
intracellular signaling cascades to control proliferation and differentiation.  Focal 
adhesion complexes are comprised of structural proteins such as vinculin and talin, and 
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signaling molecules including focal adhesion kinase (FAK) and Src [105].  Bound 
integrins, along with growth factors can also activate the MAPK signal transduction 
pathway [106-108].
In vitro, it has been shown that modifications to Ti substrate microarchitecture 
has an effect on the attachment and differentiation of osteoblast-like cells, including 
MG63 and MC3T3-E1 cell lines, as well as fetal rat calvarial cells and normal human 
osteoblasts [109].  MG63 cells exhibit stronger attachment to Ti substrates with average 
roughness values (Ra) between 4–7 µm than do cells cultured on smooth Ti substrates. 
While cell attachment appears to be stronger on rough Ti substrates, cell proliferation is 
decreased and differentiation is increased, as these cells display  increased alkaline 
phosphatase specific activity  and osteocalcin production [110].  Further, MG63 
osteoblast-like cells cultured on rough Ti surfaces release increased levels of local bone 
regulatory factors, including osteoprotegerin (OPG), prostaglandin E2 (PGE2), and 
transforming growth factor β1 (TGF-β1).  Taken together, these results indicate that 
rough Ti substrates promote osteoblast differentiation and maturation to a greater extent 
than smooth Ti surfaces.
In addition to surface roughness, surface free energy  of Ti substrates also plays 
a role in regulating bone cell responsiveness.  Ti surfaces naturally  have a low surface 
free energy  due to the adsorption of hydrocarbons and carbonates from the ambient 
atmosphere onto the TiO2 surface layer.  This adsorption also makes the Ti surfaces 
hydrophobic.  Modification of Ti surfaces can be done to create a more hydrophilic 
surface with a high surface free energy  [111].  MG63 cells cultured on high surface free 
energy  substrates show an enhanced response to Ti surface microtopography.  On 
microrough, high surface free energy  Ti substrates, these cells show increases in 
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alkaline phosphatase specfic activity, osteocalcin production, and levels of TGF-β1 and 
OPG compared to rough Ti surfaces alone [112].  
In vivo, Ti substrates with a rough microtopography  support greater bone-to-
implant contact than smooth surfaces do, resulting in greater removal torque strength 
[[113-115]].  Preliminary  studies have indicated that high surface free energy Ti surfaces 
have the potential to improve the early  stages of soft- and hard tissue integration of 
implants in vivo [116].  
1.4  Bone Graft Substitutes
! The biological processes involved in bone regeneration generally  require three 
critical components:  (1) an ostegenic potential capable of providing progenitor cells to 
the newly  forming bone, (2) osteoinductive factors, and (3) an osteoconductive scaffold 
to promote neovascularization and support new bone growth [117].  Autologous bone 
grafts are considered the “gold standard” in the field of bone graft substitutes, however 
limited donor availability  and donor site morbidity  and pain have necessitated the use of 
other materials including ceramics, allografts, osteoinductive factors, and demineralized 
bone matrix for use in filling osseous defects.
1.4.1 Demineralized bone matrix
! Demineralized bone matrices (DBM) are generated by acid extraction of bone, 
resulting in the loss of much of the mineralized component of bone but retaining collagen 
I and other non-collagenous proteins [117].  DBM is known to possess both 
osteoconductive and osteoinductive factors.  Among the osteoinductive factors in DBM 
are the bone morphogenic proteins (BMPs).  It is well documented that the levels of 
BMPs in DBM vary from donor to donor resulting in differences in osteogenic potential in 
vivo [118-120].  While DBM is known to be osteoinductive, the particulate, powdery 
nature of DBM results in poor handling qualities and a lack of structural strength for use 
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in bone defects.  To improve its handling qualities for use in surgical procedures, DBM is 
often combined other materials, including calcium sulfate, glycerol, gelatin, and 
hyaluronic acid [121, 122].
1.4.2 Hyaluronic acid!
Hyaluronic acid is a high molecular weight (104 – 107 Da), negatively  charged, 
non-sulfated glycosaminoglycan consisting of repeating units of N-acetylglucosamine 
and D-glucuronic acid [123].  It is a component of the extracellular matrix (ECM) 
expressed in nearly  all tissue types [123] and plays an important role in tissue 
morphogenesis and healing [124, 125].  During wound healing, native hyaluronic acid 
serves as an anti-angiogenic molecule, inhibiting endothelial cell proliferation and 
migration [126].  These observations have lead to the use of the sodium salt of 
hyaluronic acid (NaHY) in a number of wound healing applications [127].  Although 
NaHY inhibits capillary  formation in a three dimensional collagen gel [126, 128], low 
molecular weight degradation products of NaHY have been demonstrated to stimulate 
vascular endothelial cell proliferation [129-133], migration [134], collagen synthesis 
[135], sprout formation [136], and new blood vessel formation [137].
1.5  Thesis Objective
! It is well known that Ti surface microarchitecture and chemical composition affect 
osteoblast differentiation in vitro and bone formation in vivo.  Ti substrates that present a 
microrough surface topography combined with a high surface free energy  reduce the 
proliferation of osteoblasts and increase their production of osteocalcin, a late marker of 
osteoblast differentiation.  In addition, cells cultured on microrough Ti substrates show 
enhanced production of local factors that generate an osteogenic microenvironment 
including prostaglandin E2, TGF-β1 and osteoprotegerin.  However, the clinical success 
of implanted materials is dependent not only  upon osseointegration but also on 
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neovascularization in the peri-implant bone.  Bone is a highly vascularized tissue, and 
osteoblasts express and secrete several growth factors that are known to play  a role in 
neovascularization, including VEGF-A, FGF-2, and Ang-1.  How biomaterial properties 
may influence the response of cells to enhance neovascularization in the peri-implant 
space is not well known.  An understanding of this process could allow bioengineers to 
better design orthopaedic materials to promote both osteogenesis as well as 
neovascularization, potentially  resulting in better implant fixation and longer implant 
lifetimes.
! The purpose of this thesis is to develop an understanding as to how biomaterials 
regulate cellular response to elicit a pro-vasculogenic environment at the cell-surface 
interface, and the mechanism by which this process occurs.  In addition, one aim of this 
thesis is to understand the specific role of VEGF-A in osteoblast cell response to 
biomaterial surface features.  Finally, this thesis aims to investigate the host vascular 
response to implanted biomaterials in vivo.
! The first aim of this thesis (Chapter 2) uses in vitro cell culture techniques and a 
novel in vivo bone formation model, the murine femoral press-fit model, to examine 
whether biomaterial surface topography or surface free energy  affects the angiogenic 
response of cells or tissues at the bone/implant interface.  The results indicate that a 
rough surface microtopography  combined with a high surface free energy  enhance the 
secretion of pro-angiogenic growth factors by osteoblast-like cells in vitro and enhance 
both bone formation and neovascularization in vivo.  Further, this aim uses shRNA 
techniques to specifically  knockdown several integrin subunits expressed by osteoblasts 
to determine if signaling through integrin receptor complexes mediates the expression of 
pro-angiogenic growth factors (Chapter 3).  Silencing of the α2, α5, or β1 integrin subunits 
resulted in an increase in the production of VEGF-A compared to wild-type MG63 cells 
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while silencing of the α1 integrin subunit decreased production of VEGF-A. The results 
suggest that signaling through specific integrin receptors affects the production of 
angiogenic growth factors by osteoblast-like cells.
! The second aim of this thesis (Chapter 4) uses molecular biology techniques, 
including shRNA transduction to silence VEGF-A and treatments with neutralization 
antibodies and exogenous growth factors to determine the specific role of VEGF-A in 
osteoblast-like cell response to surface microtopography  and surface energy.  The 
results indicate that VEGF-A produced by  osteoblast-like cells has both an autocrine and 
paracrine effect.  VEGF-A silenced cells exhibited reduced production of both pro-
angiogenic and osteogenic growth factors in response to surface microtopgraphy and 
surface energy, and conditioned media from VEGF-A silenced osteoblast-like cell 
cultures failed to stimulate endothelial cell differentiation in an in vitro model.
! The third aim of this thesis (Chapter 5) uses the in vivo bone marrow ablation 
model to determine whether neovascularization in response to an implanted osteogenic 
biomaterial can be modulated in vivo using three-dimensional micro-computed 
tomography  (µCT) to analyze vascular morphology  and bone formation during healing. 
The results show that a combination of low molecular weight sodium hyaluronate 
(NaHY), an angiogenic biomaterial, as a carrier for demineralized bone matrix, an 
osteogenic stimulus, can enhance both neovascularization and bone formation during 
healing.
! The results of this thesis demonstrate that biomaterial properties affect the 
angigogenic response of cells in vitro and can enhance neovascularization in vivo. 
However, the results of this thesis raise further questions as to the specific interactions 
between cells and the biomaterial that elicit this response as well as how osteoblasts 
and endothelial cells interact during bone formation following implant insertion.  Overall, 
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the results further the understanding of how biomaterials regulate cell and tissue 
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CHAPTER 2:  Regulation of Angiogenesis During Osseointegration by 
Titanium Surface Microstructure and Energy
2.1  Introduction!
Biomaterial surface properties play  a significant role in determining host cellular 
responses to implant materials used in tissue engineering and regenerative medicine 
applications.  Modifications to surface microarchitecture, chemistry, or energy  can alter 
cell adhesion, proliferation, and gene expression [1-3]. By  designing materials to present 
specific surface properties, there is the potential to control cell responses to achieve the 
desired application.
Titanium (Ti) is a widely  used biomaterial in the orthopaedic and dental industries 
because of the biocompatibility  and resistance to wear of the Ti oxide layer that forms on 
its surface.  In vitro studies have shown that modifications to Ti surface microtopography 
affect the attachment and differentiation of osteoblasts, including MG63 and MC3T3-E1 
cell lines, as well as fetal rat calvarial cells and normal human osteoblasts [4]. MG63 
cells cultured on Ti surfaces with microrough topographies that resemble osteoclast 
resorption pits display  a more differentiated phenotype than cells grown on smooth Ti 
substrates, characterized by  decreased alkaline phosphatase specific activity  and higher 
levels of osteocalcin [5]. The combination of microstructure and high surface energy 
further enhances osteoblast differentiation on Ti surfaces [6]. In vivo, microstructured 
implant surfaces support greater bone-to-implant contact than smooth surfaces do, 
resulting in greater removal torque strength [7-9].
The overall success of biomaterial implants in orthopaedic and dental 
applications however, is not only  dependent on achieving the desired cellular response 
at the host tissue/implant interface but also by  the integration of the implant into the 
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surrounding host tissue.  Angiogenesis, the sprouting of new capillary  blood vessels from 
the pre-existing vasculature, is a critical process during embryonic development and in 
several physiological conditions, including the formation of new bone and bone fracture 
healing [15,16], as well as during bone regeneration and osseointegration of implanted 
materials [17]. This suggests that materials that support peri-implant bone formation may 
support angiogenesis as well as osteogenesis.
The formation of blood vessels in vivo is a complex process and involves the 
coordination of multiple growth factors and events.  Among the many  identified growth 
factors that serve to initiate and control angiogenesis are vascular endothelial growth 
factor-A (VEGF-A) [18], basic fibroblast growth factor (FGF-2) [19], epidermal growth 
factor (EGF) [20], and angiopoietin-1 (Ang-1) [21]. Both VEGF-A and FGF-2 are two of 
the growth factors necessary  for initiating angiogenesis and both are chemotactic for 
endothelial cells [22]. VEGF-A is produced by multiple cell types, including osteoblasts 
[23] and hypertrophic chondrocytes [24], and affects vascular permeability  in vivo [25]. 
The interaction of VEGF with its receptors Flt-1 and Flk-1/KDR is one of the first signal 
transduction pathways activated during angiogenesis in endothelial cells [26]. FGF-2 is a 
heparin-binding polypeptide that induces proliferation, migration, and protease 
production in cultured endothelial cells and promotes neovascularization in vivo [27]. 
EGF has also been implicated in angiogenesis by  stimulating the proliferation of 
endothelial cells through its interaction with the tyrosine kinase EGF receptor [28]. EGF 
treatment of prostate cancer cells increases VEGF mRNA expression suggesting that 
EGF may  also exert its effect by  stimulating VEGF production [29]. Ang-1, a member of 
the angiopoietin family  of signaling molecules, binds to its cognate receptor tyrosine 
kinase Tie1 present on the surface of endothelial cells, inducing signaling events that 
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serve to control later stages of blood vessel formation, such as the stabilization of the 
endothelial sprout and its interaction with pericytes [30].
Recent studies suggest that osteoblasts may play  a role in directly  stimulating 
endothelial cells.  Osteoblasts produce VEGF-A [31] and FGF-2 [32], and levels of these 
angiogenic factors are regulated by  factors that stimulate osteogenesis in vivo, including 
1,25 dihydroxyvitamin D3 [1,25(OH)2D3] [33], 17β-estradiol [34], and bone 
morphogenetic protein-2 (BMP-2) [35].  Others have noted that neovascularization is 
increased in peri-implant bone when microstructured Ti implants are used [36].
Mesenchymal stem cells (MSCs) that have been induced to become osteoblasts 
produce greater levels of angiogenic factors than unstimulated MSCs [37].  This 
suggests that this is a function of mature secretory  cells and those factors that enhance 
osteoblast differentiation may also enhance their ability  to promote angiogenesis.  While 
it has been established that Ti surface properties influence osteoblast maturation and 
differentiation and enhance osseointegration in vivo, the potential role that surface 
properties may have in enhancing angiogenesis surrounding the implant surface through 
the secretion of angiogenic stimulators by osteoblasts has not been investigated.
In this study, we examined the production of the pro-angiogenic growth factors 
VEGF-A, FGF-2, EGF and Ang-1 by  MG63 human osteoblast-like cells and normal 
human osteoblasts cultured on Ti surfaces with varying microtopographies and surface 
energies. In addition, we investigated whether surface-dependent production of those 
factors is sensitive to systemic regulation by  treating the cells with 1α,25(OH)2D3.  We 
verified that factors produced by  the cells were angiogenic by  assessing endothelial cell 
differentiation in response to the conditioned media from MG63 cell cultures from the 
different Ti substrates.  The specific contribution of VEGF-A was determined by  treating 
the endothelial cell cultures with conditioned media in the presence of a neutralization 
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antibody  to VEGF-A.  Finally, the effect of titanium substrate microtopography and 
surface energy on bone formation and vascularization in vivo was examined using a 
novel murine femoral press-fit model.
2.2  Materials and Methods
2.2.1 Ti Surfaces
Ti disks were prepared from 1 mm thick sheets of grade 2 unalloyed 
commercially  pure Ti punched into 15mm diameter disks and supplied by  Institut 
Straumann AG (Basel, Switzerland).  The production and characterization of smooth 
pretreatment (PT), sand blasted and acid etched (SLA), and modified SLA (modSLA) 
surfaces have been described previously  [6].  PT surfaces were degreased by washing 
Ti disks in acetone and processed in a 2%  ammonium fluoride/2%  hydrofluoric acid/10% 
nitric acid solution.  SLA surfaces were made by coarse grit-blasting of the PT surfaces 
with 0.25-0.50 mm corundum grit followed by  acid etching.  modSLA surfaces were 
made using the same procedure as SLA surfaces under nitrogen rinsing to prevent 
exposure to air and were then stored under aqueous conditions  under nitrogen to retain 
high surface free energy.  The PT surface has an overall average roughness (Ra) of less 
than 0.7 µm.  SLA and modSLA surfaces have a complex microtopography  with craters 
varying from 30 to 100 µm in diameter overlaid with pits from 1 to 3 µm in diameter.  The 
acid etch creates sharp edges approximately  700 nm in height, resulting in an overall Ra 
of approximately 4 µm.  PT, SLA and modSLA Ti disks all have a TiO2 surface layer, with 
the PT and SLA surfaces being hydrophobic due to the adsorption of atmospheric 
hydrocarbons while the modSLA surface is hydrophilic.  Advancing contact angles were 
used to calculate the hydrophilicity  of the surfaces as PT (95.8o), SLA (139.80o), and 
modSLA (~0o).  Surface free energy  for PT, SLA, and modSLA surfaces was calculated 
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according to Zisman (critical surface tension), Equation of State (EOS), and Geometric 
Mean approaches and is described in detail elsewhere [38].
Surface treatments for Ti implants for in vivo studies were prepared in a manner 
similar to those for Ti surfaces described above.  Ti implants consisted of two parts:  a 
handling device and the Ti implant rod [46].  Cylindrical Ti implants were manufactured to 
be 5 mm in length and 0.9 mm in diameter.  All implants were sterilized by  gamma 
irradiation at 25 kGy prior to use.
2.2.2 Cell Culture
Human MG63 osteoblast like cells were cultured in 24-well tissue culture plates 
on tissue culture treated polystyrene (TCPS, used as a control for all studies), PT, SLA, 
and modSLA surfaces using Dulbeccoʼs modified Eagleʼs medium (DMEM) 
supplemented with 10% fetal bovine serum and 1%  penicillin/streptomycin.  Cells were 
seeded at an initial density  of 10,000 cells/cm2 and media were exchanged 24 hours 
after seeding and every 48 hours thereafter.  When the cells were confluent on TCPS, 
media from all cultures were collected and examined for VEGF-A, FGF-2, EGF, Ang-1 
and osteocalcin levels.  Additionally, conditioned media from MG63 cell cultures were 
used to assess differentiation of human aortic endothelial cells as described below.
Primary human osteoblasts (HOB cells) were isolated from the mandible of a 50 
year old male donor by  use of an explant culture.  Briefly, isolated bone chips were 
cleaned of all soft and connective tissues and cut into approximately 1.5 mm fragments. 
The bone fragments were then cultured in DMEM containing 10% fetal bovine serum 
and 1% penicillin/streptomycin for two weeks to allow cells to migrate out of the tissue. 
The migrated osteoblasts were then collected and cultured in DMEM containing 10% 
FBS and 1% penicillin/streptomycin.  Fourth passage human osteoblasts were used for 
experiments.
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2.2.3 Effect of 1,25(OH)2D3
Confluent MG63 cell cultures were treated with 10-8M or 10-9M 1α,25(OH)2D3 or 
vehicle for 24 hours prior to harvest.
2.2.4 Cell Number
Cell number was determined for all cell types at time of harvest.  At confluence or 
after 24 hour treatment with 1α,25(OH)2D3, cells were released from TCPS and Ti 
surfaces using two sequential incubations with 0.25% trypsin for 10 minutes at 37oC to 
ensure that no cells remained on the rough Ti surfaces and counted using an automated 
cell counter (Z1 Particle counter, Beckman Coulter, Fullerton, CA).
2.2.5 Alkaline Phosphatase Specific Activity
Alkaline phosphatase specific activity  (orthophosphoric monoester 
phosphohydrolase, alkaline; E.C. 3.1.3.1) was measured in the cell lysates as a marker 
of osteoblastic differentiation.  Enzyme activity  was determined using a colorimetric 
assay measuring the release of p-nitrophenol from p-nitrophenylphosphate at 37oC. 
Samples were read on a plate reader at 415nm [39].
2.2.6 Osteocalcin
Osteocalcin levels in the conditioned medium of MG63 cells and human 
osteoblasts grown on Ti surfaces were determined as a marker of osteoblast maturation 
using a commercially  available radioimmunoassay  (Biomedical Technologies, Inc., 
Stoughton, MA) following the manufacturerʼs protocol.
2.2.7 VEGF-A, FGF-2, EGF, Ang-1
The levels of the angiogenic growth factors VEGF-A, FGF-2, EGF, and Ang-1 
were determined in the conditioned medium using commercially  available sandwich 
ELISA assays (Duoset ELISA Development Systems, R&D Systems, Minneapolis, MN) 
following the manufacturerʼs protocols.
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2.2.8 Endothelial Cell Differentiation
To determine if the conditioned media were angiogenic, we examined their ability 
to support endothelial tube formation.  Human aortic endothelial cells (HAEC) were 
purchased from Lonza (Walkersville, MD) and grown in 75cm2 tissue culture flasks using 
endothelial cell basal medium (EGM-2, Lonza).  At confluence, cells were passaged and 
used for the endothelial tube formation assay.  Endothelial cell differentiation was 
assessed using two separate assays; a Matrigel tube formation assay  (Millipore, St. 
Charles, MO), and a fibrin gel assay (Millipore).
2.2.9 Matrigel Tube Formation Assay
Briefly, 50 μL ECMatrixTM was added to each well of a 96-well tissue culture plate 
and allowed to solidify  for 1 hour at 37oC.  HAECs were then seeded at a density  of 1 X 
104 cells/well using a mixture of 100μL conditioned medium from MG63 cells cultured on 
TCPS, PT, SLA, and modSLA surfaces and 50μL EGM-2 for growth maintenance.  Cells 
were cultured for 24 hours, and at 4, 8, 12, and 24 hours after seeding, pictures were 
taken for morphometric analysis to determine the total endothelial tube length and total 
number of branch points.
To assess the specific role of VEGF-A, endothelial cell differentiation in the 
presence of a competitive VEGF-A blocking antibody  was determined.  Goat anti-human 
VEGF-A neutralization antibody  was purchased from R&D Systems (Minneapolis, MN) 
and was added to the culture medium at a concentration of 5 μg/mL.
2.2.10 Fibrin Gel Assay
Endothelial cell differentiation was further assessed with the use of a fibrin gel 
assay.  30 µL of fibrinogen solution and 20 µL of thrombin solution were added to each 
well of a 96-well plate and the mixture was allowed to polymerize for 30 minutes at 37oC. 
HAECs were plated in 100 µL of EGM-2 at a density  of 5 x 103 cells/well and cultured at 
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37oC for 24h.  At 24h, media were removed and a second layer of fibrin was added on 
top of cells by again mixing 30 µL of fibrinogen and 20µL of thrombin.  The mixture was 
allowed to polymerize for 5 minutes before 100 µL of conditioned media from MG63 cell 
cultures on Ti substrates was added.  At 12, 24, 36, and 48h after the addition of 
conditioned media, images were taken for morphometric analysis to determine total 
endothelial tube length.
2.2.11 In vivo model
! All animal handling and procedures were approved by  the Georgia Institute of 
Tehnology  IACUC review board and conducted in accordance with NIH guidelines. 
Custom-made Ti implants were inserted into the femoral medullary  canal of mice via a 
medial parapatellar arthrotomy.  Briefly, male C57/Bl6 mice (ages 8 weeks or 9 months) 
were anesthetized with 5% isoflurane gas inhalation.  The right hind limb of animals was 
shaved and cleaned using ethanol and chlorhexidine.  Anesthetization was maintained 
with 2% isoflurane gas inhalation for the duration of the surgical procedure.  Cleaned, 
anesthetized animals were placed in a supine position and covered with a sterile surgical 
drape.   Using a scalpel, an 8 mm incision was made over the distal side of the knee. 
Blunt dissection was used to move aside the ligament and patella to expose the 
intercondyler notch of the distal femur.  Once the femoral cartilage was exposed, a 1 mm 
round dental bur was used to penetrate the distal intercondylar notch of the femur to 
access the medullary  cavity.  A 22G needle was gently  pushed into the femur to confirm 
penetration of the medullary  cavity.  Cylindrical Ti implants were inserted into the femoral 
medullary  canal and broken from the handling device.  To confirm successful insertion of 
the implant into the femoral medullary  canal, x-ray imaging was done prior to closure of 
the surgical incision.  If the Ti implant was not inserted into the medullary  canal or if 
insertion of the Ti implant resulted in a broken femur, the mouse was removed from the 
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study  and euthanized using CO2 inhalation.  This was done to ensure an appropriate 
number of successful surgeries for each Ti implant type.  Following successful implant 
insertion, periosteal tissue was closed using resorbable sutures and the surgical incision 
was closed with wound clips.  After recovery from anesthesia, mice were injected with 
0.03 mg/kg buprenorphine to relieve post-operative pain.  Animals were monitored every 
12 hours for 48 hours post-surgery  and once per day  thereafter for the duration of the 
study.  Wound clips were removed 10-14 post-surgery.  All animals had access to food 
and water ad libitum for the duration of the study.  
2.2.12 Vascular Perfusion
! At 28 days post-surgery, 9 month-old animals were euthanized via CO2 
inhalation.  Immediately  after euthanization, the thoracic cavity  was opened and a 22G 
butterfly  needle was inserted into the left ventricle.  The inferior vena cava was severed 
to allow for the vasculature to be flushed.  Heparanized saline (100 U/mL) was used to 
flush the vasculature followed by  perfusion with 10% neutral buffered formalin to fix the 
tissue specimens.  The vasculature was perfused using a radio-opaque silicone rubber 
compound (Microfil, Flow  Tech Inc., Carver, MA) consisting of a 9:1 ratio of 
Microfil:curing agent.  Following vascular perfusion, the injected Microfil compound was 
allowed to polymerize overnight at 4oC.  
2.2.12 Implant Harvest
! At 28 days (9 month mice) or 35 days (8 week mice) limbs containing Ti implants 
were collected and stored in 10% neutral buffered formalin for histological processing. 
Sagittal tissue sections were cut and polished to a final thickness of 10 – 20 µm and 
stained with haematoxylin and eosin for histological analysis.
Using commercially  available image analysis software (Image-Pro, MediaCybernetics, 
Bethesda, MD) stained tissue sections were analyzed for bone to implant contact (both 8 
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week and 9 month old animals) as well as total blood vessel number (9 month old 
animals).
2.2.13 Statistical Analysis
The data presented here are from one of two separate sets of experiments.  Both 
sets of experiments yielded comparable observations.  For any given experiment, each 
data point represents the mean + standard error of six individual cultures.  Data were 
analyzed by  ANOVA and when statistical differences were detected, Studentʼs t-test for 
multiple comparisons using Bonferroniʼs modification was used.  p-values < 0.05 were 
considered significant.
2.3  Results
2.3.1 MG63 and HOB Cell Response
As noted previously  [6], MG63 cell differentiation was increased on the SLA and 
modSLA substrates compared to cells on TCPS and PT, validating the model.  Total cell 
number was comparable on TCPS and smooth PT surfaces, whereas cells cultured on 
microrough SLA Ti surfaces demonstrated a significant decrease (p<0.05) in cell number 
when compared to TCPS and smooth PT Ti surfaces (Figure 2-1A).  The addition of high 
surface energy on modSLA Ti surfaces did not result in any  further decrease in overall 
cell number.  MG63 cells exhibited a more differentiated phenotype when grown on Ti 
substrates compared to TCPS.  Alkaline phosphatase specific activity  on all three Ti 
substrates was significantly  reduced (Figure 2-1B).  Osteocalcin, a late marker of 
osteoblast differentiation was found to be similar on TCPS and smooth PT substrates, 
and was increased 212% in MG63 cell cultures on SLA (Figure 2-1C).  The combination 
of high surface energy  and microstructure on modSLA surfaces resulted in a further 
increase in osteocalcin levels compared to SLA.
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Secretion of angiogenic factors by  MG63 cells was differentially  regulated as a 
function of substrate morphology  and surface energy.  Secreted levels of VEGF-A on 
TCPS and PT substrates were comparable (Figure 2-2A).  Levels of secreted VEGF-A 
increased nearly  2-fold on SLA while MG63 cell cultures produced almost 3-fold higher 
levels of VEGF-A on modSLA.  Secretion of FGF-2 and EGF exhibited similar substrate-
dependent effects.  FGF-2 levels were similar on both TCPS and PT substrates; 
secreted levels observed on SLA were approximately  10-fold higher than TCPS levels; 
and the combination of a hydrophilic surface with the rough surface microstructure 
observed on modSLA resulted in a further enhancement of FGF-2 production (Figure 
2-2B).  EGF production on SLA and modSLA was significantly  higher than on either 
TCPS or PT (Figure 2-2C).  In contrast to secreted levels of VEGF-A, FGF-2, and EGF, 
the levels of Ang-1 were comparable on all surfaces examined (Figure 2-2D).
HOB cells cultured on TCPS as well as on all three Ti surfaces exhibited similar 
responses to those observed in MG63 cell cultures.  Total cell number on TCPS was 
significantly  higher than that observed on all three Ti substrates (Figure 2-3A).  Further, a 
rough microstructure reduced total cell number compared to smooth pre-treated Ti 
surfaces.  High surface energy further reduced total cell number on modSLA surfaces.
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Figure 2-1.  Response of MG63 cells cultured on tissue culture polystyrene and Ti 
surfaces:  (A) cell number, (B) alkaline phosphatase specific activity  in the cell lysate, 
and (C) osteocalcin levels in the conditioned medium.  Cells were cultured on control 
(TCPS), PT, SLA, and modSLA Ti surfaces.  Values presented are mean + SEM of six 
independent cultures.  The data presented are from one of two separate experiments 
with comparable results.  Data were analyzed using ANOVA and statistical significance 
between groups was determined using Bonferroniʼs modification of Studentʼs t-test.  *p< 
0.05 vs. TCPS; ·p<0.05 vs. PT; Φp<0.05 vs. SLA.
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Figure 2-2.  Production of angiogenic growth factors by  MG63 cells on tissue culture 
polystyrene and Ti surfaces:  (A) VEGF-A, (B) FGF-2, (C) EGF, and (D) Ang-1 levels 
were determined in the conditioned medium by ELISA.  Cells were cultured on control 
(TCPS), PT, SLA, and modSLA Ti surfaces.  Values presented are mean + SEM of six 
independent cultures.  The data presented are from one of two separate experiments 
with comparable results.  Data were analyzed using ANOVA and statistical significance 
between groups was determined using Bonferroniʼs modification of Studentʼs t-test.  *p< 
0.05, vs. TCPS; ·p<0.05, vs. PT; Φp<0.05, vs. SLA.
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Figure 2-3.  Characterization of normal human osteoblasts cultured on TCPS, PT, SLA, 
and modSLA Ti surfaces:  (A) cell number, (B) osteocalcin, and (C) VEGF-A levels in the 
conditioned medium.  Values presented are mean + SEM of six independent cultures. 
The data presented are from one of two separate experiments with comparable results. 
Data were analyzed using ANOVA and statistical significance between groups was 
determined using Bonferroniʼs modification of Studentʼs t-test.  *p< 0.05 vs. TCPS; 
·p<0.05 vs. PT; Φp<0.05 vs. SLA.
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Osteocalcin production by  HOB cells on TCPS and PT substrates was comparable, 
while osteocalcin levels increased approximately  1.6 fold and 3.5 fold on SLA and 
modSLA surfaces, respectively  (Figure 2-3B).  Similarly, VEGF-A levels were 
comparable on TCPS and PT.  Secreted VEGF-A levels were doubled on SLA 
substrates, while cultures on modSLA surfaces showed increased levels over SLA 
(Figure 2-3C).  Levels of FGF-2 and EGF in the conditioned media of cells grown on all 
substrates were undetectable by ELISA (data not shown).
Treatment of MG63 cells with the vitamin D metabolite 1α,25(OH)2D3 caused a 
dose dependent increase in both osteocalcin (Figure 2-4A) and VEGF-A (Figure 2-4B) 
on all surfaces in addition to the increase observed in response to Ti surface 
microstructure.  The effects of surface roughness and 1α,25(OH)2D3 were synergistic for 
both osteocalcin and VEGF-A.  No effect of 1α,25(OH)2D3 on FGF-2 and EGF was 
observed regardless of substrate (data not shown).
2.3.2 Endothelial Cell Differentiation
Conditioned media from MG63 cell cultures affected endothelial tube formation in 
a Matrigel® tube formation assay  in a substrate dependent manner.  Conditioned media 
from all three Ti substrates caused a greater degree of endothelial cell differentiation 
than conditioned media from cells grown on TCPS based on total endothelial tube length 
(Figure 2-6A).  Moreover, surface energy  had a further stimulating effect.  Using the 
number of branch points (the number of points where endothelial networks split into two 
or more tube like structures) as another marker of endothelial cell differentiation, we 
found that at 4h of culture, the number of branch points induced by  conditioned media 
from all Ti substrates was significantly  higher than those observed in the presence of 
TCPS media.  Media from cultures grown on SLA increased the number of endothelial 
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Figure 2-4.  Effect of 1α,25 (OH)2D3 treatment on MG63 cell differentiation.  MG63 cells 
were cultured on TCPS, PT, SLA, and modSLA Ti surfaces.  At confluence, cultures were 
treated with 10-9M or 10-8M 1α,25 (OH)2D3 for 24 hours.  (A) Osteocalcin and (B) VEGF-
A levels in the conditioned medium were determined.  Values are mean + SEM of six 
independent cultures.  The data presented are from one of two experiments with 
comparable results.  Data were analyzed using ANOVA and statistical significance 
between groups was determined using Bonferroniʼs modification of Studentʼs t-test. *p< 
0.05 vs. TCPS; ·p<0.05 vs. PT; Φp<0.05 vs. SLA.
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branch points observed versus media from PT substrates (SLA vs. PT), and media from 
cultures on the high surface energy substrate caused a further increase in endothelial 
branch points (modSLA vs. SLA).
The increase in endothelial cell differentiation seen at earlier time points in 
response to conditioned media from cultures grown on SLA and modSLA surfaces was 
due in part to an increase in the levels of VEGF-A.  Addition of a VEGF-A neutralization 
antibody  to conditioned media from these cultures reduced endothelial cell differentiation 
to levels observed using conditioned media from TCPS cultures in the absence of 
antibody  (Figure 2-6B).   Results from the fibrin gel assay  further demonstrate that there 
were increased levels of pro-angiogenic growth factors in the conditioned media of 
MG63 cell cultures on Ti substrates.  Similar to the Matrigel® assay, endothelial cells 
cultured in media from all three Ti substrates exhibited a greater degree of differentiation 
as determined by  tubular network length after 36h of cultured within a fibrin gel network 
(Figure 2-5 and Figure 2-6C).  There were no significant differences in total tube length 
between the different Ti substrates however.
2.3.3 In vivo results
! Bone formation and osseointegration surrounding PT, SLA, and modSLA 
implants was examined using a femoral intramedullary  bone formation model.  Implants 
were designed and manufactured to fit into the medullary  canal of C57/Bl6 mice (Figure 
2-7A).  Implants were successfully  inserted into the medullary  space without breaking 
the femur (Figure 2-7B,C).  After 35 days (8 week-old mice) or 28 days (9 month-old 
mice), limbs were harvested and cut for histological analysis of new bone formation as 
well as neovascularization (Figure 2-8).  New  bone formation around PT, SLA, and 
modSLA implants in vivo was affected by  the age of the animals.  For both 8 week and 9 
month-old mice, neither surface microstructure nor surface energy  had an effect on bone 
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to implant contact where the implant surface came in direct contact with the femoral 
cortical bone surface (Table 2-1).
Table 2-1:  Cortical Surface Bone to Implant Contact
Surface Type 8 Week 9 Month
PT 0.88 + 0.06 0.89 + 0.06
SLA 0.87 + 0.05 0.89 + 0.07
modSLA 0.92 + 0.07 0.93 + 0.07
!
! Ti surface microstructure nor surface energy had an effect on the marrow bone to 
implant contact (BIC) in 8 week old, male, C57/Bl6 mice, which are young, physically 
mature animals (Figure 2-7A).  In 9 month-old C57/Bl6 male mice, which are considered 
an aged animal model, increased surface microtopography  alone had no effect on total 
BIC within the femoral marrow cavity, however total BIC  was significantly increased in 
response to the surface microtopography  and high surface energy  seen on modSLA Ti 
implants compared to smooth PT Ti implants (Figure 2-7A).  Additionally, the total 
number of blood vessels within the marrow space surrounding Ti implants was also 
increased in the modSLA implant group relative to smooth PT controls (Figure 2-7B).
2.4  Discussion
Angiogenesis is an essential process for the clinically  successful integration of 
orthopaedic and dental implants.  Here we demonstrate that the surface properties of 
biomaterials affect cellular response with regard to the production of pro-angiogenic 
growth factors and show that these factors stimulate endothelial cell differentiation. 
These observations suggest that microstructured, high energy  surfaces induce 
angiogenesis during osseointegration.  
! Our results show that in addition to producing increased levels of VEGF-A on 
SLA and modSLA [40], MG63 cells also produce increased FGF-2 levels on these 
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substrates.  Part of the increase is due to microstructure and part is due to surface 
energy.  MG63 cells produce elevated levels of EGF as well, but this effect is due 
primarily  to substrate microstructure since no further increase was seen on modSLA. 
Not all angiogenic factors are regulated in this manner, however, either as a function of 
surface chemistry  or surface microarchitecture.  Levels of angiopoeitin-1 were 
comparable in the conditioned media of all cultures examined.
! The human osteoblasts used in the present study exhibited marked increases in 
VEGF-A when grown on SLA and further increases when grown on modSLA, but unlike 
the MG63 cells they  did not exhibit substrate dependent changes in FGF-2 or EGF.  We 
examined cells from only  a single human donor.  Numerous studies demonstrate the 
variability  among donors as a function of sex, age, and donor site [41,42].  In addition, it 
is likely that failure to observe such changes was because these factors were below the 
limits of detection of the assay kits we used.
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Figure 2-5.  Endothelial cell differentiation.  Representative images of endothelial cells 
cultured on a fibrin gel matrix with conditioned media from (A) TCPS, (B) PT, (C) SLA, 
and (D) modSLA cultures of MG63 cells.
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Figure 2-6.  Endothelial cell differentiation.  Endothelial tube formation was assessed 
using both a Matrigel® tube formation assay  and a fibrin gel assay with conditioned 
medium from MG63 cells cultured on TCPS, PT, SLA, and modSLA surfaces.  (A) Total 
endothelial tube length and total number of branch points at 4h. *p< 0.05 vs. TCPS; 
·p<0.05 vs. PT; #p<0.05 vs. SLA.  (B) Addition of VEGF-A neutralization antibody  inhibits 
endothelial cell differentiation in response to MG63 conditioned media.  Endothelial tube 
formation was assessed using conditioned medium from MG63 cells cultured on TCPS, 
PT, SLA, and modSLA surfaces in the presence of a VEGF-A neutralization antibody. 
Total endothelial tube length is presented for cultures with and without the addition of 
neutralization antibody.  *p<0.05 vs. no antibody.  (C)Fibrin gel assay  total endothelial 
tube length at 24 and 36 hours. *p< 0.05 vs. TCPS; #p<0.05 vs. PT.
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Figure 2-7. Representative images demonstrating feasibility  of the mouse femoral 
intramedullary  bone formation model.  (A) Image showing the implant (arrow) and 
handling device for an SLA implant.  (B) X-ray image showing an implant that has been 
inserted into the femoral medullary  space without breaking of the bone.  (C) Gross 
morphology of a mouse femur with an implant (arrow).
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Figure 2-8. Representative histology sections for (A) PT, (B) SLA, and (C) modSLA 
titanium implants.  Marrow and cortical bone to implant contact (BIC) as well as the 
number of blood vessels in the marrow were determined for all the implant types.
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Figure 2-9.  In vivo bone formation.  Bone formation and neovascularization surrounding 
PT, SLA, and modSLA Ti implants was examined using a novel murine intramedullary 
bone formation model.  (A) The percent bone to implant contact (% BIC) was measured 
for both 2 month old and 9 month old animals.  *p<0.05 vs. PT.  (B)  The total number of 
blood vessels within the marrow space of 9 month old animals.  P<0.05 vs. PT.  Values 
presented are the mean + SEM of six implants per group. Data were analyzed using 
ANOVA and statistical significance between groups was determined using Bonferroniʼs 
modification of Studentʼs t-test.
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! Our results support the hypothesis that production of angiogenic factors is related 
to the state of osteogenic maturation of the osteoblasts.  MG63 cells and normal human 
osteoblasts exhibited a more differentiated phenotype on SLA and modSLA than on 
TCPS and PT, with reduced alkaline phosphatase and increased osteocalcin typical of 
secretory  cells.  These cells also exhibited increased production of angiogenic factors, 
suggesting that this is linked to the acquisition of a more differentiated phenotype.
The systemic osteotropic hormone 1α,25(OH)2D3 is a key regulator of bone 
metabolism [33].  Treatment of late-stage osteoblast cultures with 1α,25(OH)2D3 
upregulates expression of both alkaline phosphatase and type I collagen, markers of 
osteoblast differentiation [43].  Previous results from our laboratory  have shown that 
treatment of MG63 cells cultures with 1α,25(OH)2D3 enhances cell response to Ti 
surface microstructure [44].  Our results here support this data and further show that 
production of VEGF-A is regulated in the same manner.
Substrates that presented a microrough surface topography  and high surface 
energy  enhanced the synthesis of several pro-angiogenic growth factors, which 
subsequently  resulted in an enhancement of the differentiation of human aortic 
endothelial cells in vitro.  This supports the hypothesis that more mature osteoblasts 
produce the angiogenic factors needed to recruit a vascular supply. The addition of a 
VEGF-A neutralization antibody  to endothelial cell cultures inhibited this increase in 
endothelial cell differentiation, indicating that the increased levels of VEGF-A produced 
by  MG63 cells on SLA and modSLA substrates contributes to endothelial cell 
differentiation.
Using the murine intramedullary  bone formation model, a novel, in vivo bone 
formation model, we observed that both age as well as biomaterial surface features 
affect osseointegration and neovascularization.  In young, skeletally  mature C57/Bl6 
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mice, neither Ti surface roughness nor wettability  had a significant effect on 
osseointegration, as determined by  histological examination of total bone to implant 
contact at 35 days post-implantation.  However, in 9-month old C57/Bl6 mice, which are 
an aged model representing compromised bone, the combination of a rough surface 
microtopography and high surface energy  on modSLA substrates resulted in a significant 
increase in total bone to implant contact surrounding these implants.  In addition, when 
the vasculature of these animals was perfused and the total number of blood vessels 
surrounding the implants within the marrow  space were determined, it was found that 
modSLA implants significantly  increased the total vessel number.  These results are 
consistent with results found previously demonstrating that healing abilities are 
diminished with age [47].
In a clinical setting, establishment of a vasculature preceding or concomitant with 
bone formation allows for not only the delivery  of oxygen, systemic hormones, and 
nutrients to the injury  site but also the migration of mesenchymal stem cells.  In the 
absence of neovascularization, the implant may be surrounded by  a fibrous capsule, 
resulting in implant loosening and ultimately  failure, demonstrating the importance of the 
initial reaction of the first cells to come in contact with an implanted material.
We show here that substrate microstructure and surface energy regulate the 
production of angiogenic growth factors by  osteoblasts.  The increase in endothelial cell 
differentiation observed in response to conditioned media from SLA and modSLA 
cultures further demonstrate that Ti substrate features control osseointegration by 
enhancing angiogenesis at the material/tissue interface.
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CHAPTER 3:  Integrin Mediated Signaling Regulates the Angiogenic 
Response of Osteoblasts to Titanium Substrate Features
3.1 Introduction
The initial interaction of cells with a biomaterial surface plays a significant role in 
determining host tissue response to an implanted material.  Upon implantation into the 
body, the surface of a biomaterial is conditioned with an adsorbed layer of proteins, ions, 
sugars and lipids present in the surrounding blood and tissue fluid [1, 2].  The surface 
properties of the implanted material help  to determine which biological molecules 
adsorb.  The orientation of the adsorbed biological molecules directly  influences the 
attachment, proliferation, and differentiation of surrounding cells [3].  The adhesion of 
cells with a biomaterial surface involves several classes of proteins including 
extracellular matrix proteins, cytoskeletal proteins, cadherins, and integrins [4].
Osteoblasts interact with their substrate primarily  via integrin binding to 
extracellular matrix (ECM) proteins [5].  Integrins are heterodimeric transmembrane 
glycoprotein receptor complexes consisting of non-covalently  associated α and β 
subunits.  Integrin receptors bind ECM proteins on the outside of the cell and associate 
with the cytoskeleton and signaling complexes inside the cell to transduce signals. 
Osteoblasts express several integrin α and β subunits including α1, α2, α3, α4, α5, α6, αv, 
β1, and β3 [6-8]. The expression of integrin subunits by  osteoblast-like cells is regulated 
by surface chemical composition and topography [9, 10]
Upon binding, integrin molecules cluster into focal adhesions, where they  initiate 
intracellular signaling cascades to control proliferation and differentiation.  Focal 
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adhesion complexes are comprised of structural proteins such as vinculin and talin, and 
signaling molecules including focal adhesion kinase (FAK) and Src [11].  Bound 
integrins, along with growth factors can also activate the MAPK signal transduction 
pathway [12-14].
Titanium (Ti) is a commonly  used material in the orthopaedic and dental fields 
and Ti surface microtopography  and chemical composition affect osteoblast 
differentiation in vitro and bone formation in vivo.  Ti substrates that present a 
microrough surface topography  combined with a high surface free energy  increase 
production of osteocalcin, a late marker of osteoblast differentiation in vivo and enhance 
bone-to-implant contact and removal torque strength in vivo [15-17].
On tissue culture polystyrene surfaces, osteoblasts primarily  express the α5β1 
integrin [9].  However, when grown on Ti substrates, expression of α2 and β1 integrin 
subunits is increased [10], suggesting that the surface roughness dependent 
differentiation of osteoblasts may be mediated specifically  through α2β1 signaling. 
Knockdown of either the α2 or β1 integrin subunits in MG63 cells blocks surface 
roughness dependent differentiation of those cells [18, 19], and has an effect on the 
production of pro-angiogenic growth factors [20].
Integrins also play  an important role in neovascularization.  Vascular endothelial 
cells, similar to osteoblasts, express several integrin α and β subunits in a differential 
manner [21].  In quiescent vessels, many  integrins are either not expressed or are in an 
inactive state.  During neovascularization, endothelial cells upregulate expression of 
integrin pairs that are also expressed during osteoblastic differentiation, including α1β1, 
α2β1, and α5β1 [22].  
Angiogenic growth factor receptors, including the VEGF receptor Flk-1 and the 
PDGFβ receptor have been found to interact with integrins on the surface of endothelial 
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cells during neovascularization [23].  Endothelial cell integrin pairs have also been found 
to interact directly with angiogenic growth factors including VEGF-A and FGF-2 [24, 25].  
While it is known that signaling through integrin receptors in osteoblasts has an 
effect on the differentiation and expression of osteogenic markers in response to Ti 
surface roughness and energy, whether or not integrin signaling in osteoblasts affects 
the production of angiogenic growth factors in these cells is not known.  In this study, we 
investigated the role that signaling through specific integrin receptors has on the 
production of pro-angiogenic growth factors in osteoblast-like cells in response to 
substrate microtopography  and surface free energy.  In order to elucidate the effect of 
different integrin α and β subunits, we transduced shRNA specific for integrin subunits 
α1, α2, α5, and β1 into an MG63 osteoblast like cell line to knockdown expression of 
these integrins.  We cultured wild-type MG63 cells and specific integrin silenced MG63 
cells on Ti surfaces presenting varying topographies and surface free energies and 
examined the production of both osteogenic and angiogenic growth factors.
3.2 Materials and Methods
3.2.1 Titanium substrate preparation
! Ti disks were prepared from 1 mm thick sheets of grade 2 unalloyed 
commercially  pure Ti punched into 15mm diameter disks and supplied by  Institut 
Straumann AG (Basel, Switzerland).  The production and characterization of smooth 
pretreatment (PT), sand blasted and acid etched (SLA), and modified SLA (modSLA) 
surfaces have been described previously [[26]].  PT surfaces were degreased by 
washing Ti disks in acetone and processed in a 2% ammonium fluoride/2%  hydrofluoric 
acid/10% nitric acid solution.  SLA surfaces were made by  coarse grit-blasting of the PT 
surfaces with 0.25-0.50 mm corundum grit followed by a dual acid etching procedure 
with hydrochloric acid and hydrofluoric acid.  modSLA surfaces were made using the 
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same procedure as SLA surfaces under nitrogen rinsing to prevent exposure to air and 
were then stored under aqueous conditions  under nitrogen to retain high surface free 
energy.  The PT surface has an overall average roughness (Ra) of less than 0.7 µm. 
SLA and modSLA surfaces have a complex microtopography  with craters varying from 
30 to 100 µm in diameter overlaid with pits from 1 to 3 µm in diameter.  The acid etch 
creates sharp edges approximately  700 nm in height, resulting in an overall Ra of 
approximately  4 µm.  PT, SLA and modSLA Ti disks all have a TiO2 surface layer, with 
the PT and SLA surfaces being hydrophobic due to the adsorption of atmospheric 
hydrocarbons while the modSLA surface is hydrophilic.  Advancing contact angles were 
used to calculate the hydrophilicity  of the surfaces as PT (95.8o), SLA (139.80o), and 
modSLA (~0o).  Surface free energy  for PT, SLA, and modSLA surfaces was calculated 
according to Zisman (critical surface tension), Equation of State (EOS), and Geometric 
Mean approaches and is described in detail elsewhere[27].
3.2.2 Generation of integrin silenced cell lines
Integrin α2:  Stably  silenced MG63 osteoblast-like cells for integrin α2 were 
generated by  transfection with α2 integrin shRNA using a P-suppressor-neo vector 
system and shown to have a 70% reduction in α2 protein as described in detail 
previously[[18]].  Integrin α2-silenced MG63 cells were maintained in media containing 
geneticin (G418; Invitrogen, Carlsbad, CA) at a concentration of 600 µg/mL for the 
duration of cell culture.
Integrins α1, α5, and β1:  MG63 osteoblast-like cells were transduced using 
Mission® lentiviral transduction particles (Sigma-Aldrih, St. Louis, MO) with shRNA 
specific for each target gene of interest following the manufacturerʼs recommended 
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protocol.  Verification of silencing for each integrin subunit was done using western blot 
analysis and real-time qPCR.
3.2.3 Cell Culture
! Non-transduced MG63 cells and MG63 cells silenced for integrins α1, α2, α5, and 
β1 were plated in 24-well tissue culture plates on tissue culture treated polystyrene 
(TCPS, used as a control for all studies), PT, SLA, and modSLA surfaces using 
Dulbeccoʼs modified Eagleʼs medium (DMEM) supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin.  Cells were seeded at an initial density of 10,000 
cells/cm2 and media were exchanged 24 hours after seeding and every  48 hours 
thereafter.  When the cells were confluent on TCPS, media from all cultures were 
collected and examined for VEGF-A, FGF-2, Ang-1 and osteocalcin levels.
3.2.4 Cell Number
Cell number was determined for all cell types at time of harvest.  At confluence, 
cells were released from TCPS and Ti surfaces using two sequential incubations with 
0.25% trypsin for 10 minutes at 37oC to ensure that no cells remained on the rough Ti 
surfaces and counted using an automated cell counter (Z1 Particle counter, Beckman 
Coulter, Fullerton, CA).
3.2.5 Alkaline Phosphatase Specific Activity
Alkaline phosphatase specific activity  (orthophosphoric monoester 
phosphohydrolase, alkaline; E.C. 3.1.3.1) was measured in the cell lysates as a marker 
of osteoblastic differentiation.  Enzyme activity  was determined using a colorimetric 
assay measuring the release of p-nitrophenol from p-nitrophenylphosphate at 37oC. 
Samples were read on a plate reader at 415nm.
3.2.6 Osteocalcin
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Osteocalcin levels in the conditioned medium of MG63 cells and human 
osteoblasts grown on Ti surfaces were determined as a marker of osteoblast maturation 
using a commercially  available radioimmunoassay  (Biomedical Technologies, Inc., 
Stoughton, MA) following the manufacturerʼs protocol.
3.2.7 VEGF-A, FGF-2, Ang-1
The levels of the angiogenic growth factors VEGF-A, FGF-2, and Ang-1 were 
determined in the conditioned medium using commercially available sandwich ELISA 
assays (Duoset ELISA Development Systems, R&D Systems, Minneapolis, MN) 
following the manufacturerʼs protocols.
3.2.8 Statistical Analysis
The data presented here are from one of at least two separate sets of 
experiments.  Both sets of experiments yielded comparable observations.  For any  given 
experiment, each data point represents the mean + standard error of six individual 
cultures.  Data were analyzed by  ANOVA and when statistical differences were detected, 
Studentʼs t-test for multiple comparisons using Bonferroniʼs modification was used.  p-
values < 0.05 were considered significant.
3.3 Results
3.3.1 MG63 cell response
! Consistent with previously published results, for all experiments, MG63 cells 
exhibited a decrease in total cell number and an increase in secreted levels of 
osteocalcin, VEGF-A, and FGF-2 with increasing surface roughness and hydrophilicity, 
while secreted levels of Angiopoietin-1 were unaffected by  either surface roughness or 
energy[20] (Figures 1-4).  
3.3.2 Integrin α1 silencing
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! Silencing of the α1 integrin subunit resulted in no significant differences in 
measured cell number on any  of the substrates examined (Figure 3-1A). Osteocalcin 
production increased in response to surface roughness and energy  in both wild-type 
MG63 cells and integrin α1 silenced cells, however this increase was significantly 
attenuated in integrin α1 silenced cells (Figure 3-1B) The secreted levels of angiogenic 
growth factors were affected in response to specific integrin silencing.  Secreted levels of 
VEGF-A by  integrin α1 cell cultures increased in response to the surface microroughness 
and hydrophilicity  observed on modSLA substrates compared to TCPS control cultures, 
however, secreted levels of VEGF-A in integrin α1 silenced cell cultures were 
significantly  reduced on all substrates relative to MG63 cell cultures (Figure 3-1C). 
Integrin α1 silencing had no effect on the secreted levels of FGF-2 or Ang-1 compared to 
MG63 cell cultures on TCPS, PT, or SLA substrates (Figure 3-1D,E).  On modSLA 
substrates, FGF-2 production was significantly  reduced compared to MG63 cultures 
(Figure 3-1D).  In contrast, secreted levels of Ang-1 were significantly  increased in 
integrin α1 cell cultures compared to both MG63 cell cultures on modSLA and α1 
silenced cells on TCPS (Figure 3-1E).  
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Figure 3-1.  Integrin α1 silenced cell response to Ti substrate features.  (A) Total cell 
number of integrin α1 silenced cells and MG63 wild-type cells were determined.  (B) 
Osteocalcin, (C) VEGF-A, (D) FGF-2, and (E) Ang-1 levels in the conditioned media of 
both MG63 cells and integrin α1 silenced MG63 cells were determined. Values presented 
are mean + SEM of six independent cultures.  Data were analyzed using ANOVA and 
statistical significance between groups was determined using Bonferroniʼs modification 
of Studentʼs t-test. *p<0.05 vs. TCPS; #p<0.05 vs. MG63 cultures.
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3.3.3 Integrin α2 silencing
! Total cell number for integrin α2 silenced cells were comparable to MG63 cell 
numbers on TCPS, PT, and SLA substrates.  On microrough, hydrophilic modSLA 
substrates, α2 silenced cell numbers were higher than those observed for MG63 cell 
cultures (Figure 3-2A).  Integrin α2 silencing attenuated the surface roughness and 
energy  dependent increases in osteocalcin production observed in MG63 cells but had 
no effect on secreted levels of osteocalcin on smooth TCPS or PT substrates or (Figure 
3-2B).  Unlike integrin α1 silenced cells, production of VEGF-A by  integrin α2 silenced 
cells was increased nearly  2 fold on all substrates examined (Figure 3-2C).  Integrin α2 
silencing had no effect on FGF-2 production in response to increasing surface 
microstructure but it reduced FGF-2 levels significantly  compared to MG63 cells on 
modSLA substrates (Figure 3-2D).  Similar to α1 silenced cells, secreted levels of Ang-1 
were significantly  increased by  α2 silenced cells on modSLA substrates compared to 
levels observed on TCPS and MG63 cells on modSLA, but α1 silencing had no effect on 
Ang-1 levels on any other substrates examined (Figure 3-2E).
3.3.4 Integrin α5 silencing
! Similar to the results for α2 silenced cells, integrin α5 silenced cells had 
comparable cell number to MG63 cells on TCPS, PT, and SLA substrates while cell 
number was increased on modSLA surfaces in α5 silenced cells compared to MG63 cell 
cultures (Figure 3-3A).  Secreted levels of osteocalcin, a late marker of osteoblast 
maturation, in α5 silenced cells was similar to secreted levels by MG63 cell cultures on 
all substrates (Figure 3-3B).  Silencing of the integrin α5 subunit significantly  increased 
secretion of VEGF-A by cells compared to MG63 cell cultures on TCPS, PT, and 
modSLA substrates, but no differences in secreted levels by  α5 silenced cells were 
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observed on SLA substrates compared to MG63 cells (Figure 3-3C).  No differences in 
FGF-2 and Ang-1 production by  integrin α5 silenced cell cultures were observed 
compared to MG63 cell cultures on any  substrates examined (Figure 3-3D,E).  However, 
Ang-1 production by α5 silenced cells was significantly  higher on microrough, hydrophilic 
modSLA substrates compared to smooth TCPS substrates (Figure 3-3E).
3.3.5 Integrin β1 silencing
! Total cell number in integrin β1 silenced cells was less than that observed in 
MG63 cell cultures on smooth TCPS and PT substrates but cell number was not affected 
in response to surface roughness and hydrophilicity  on SLA and modSLA substrates 
(Figure 3-4A).  Similar to α2 silencing, the surface roughness and hydrophilicity 
dependent increase in osteocalcin production seen in MG63 cells was blocked by 
silencing of the β1 integrin (Figure 3-4B).  VEGF-A production was significantly  increased 
in integrin β1 silenced cells on all substrates (Figure 3-4C).  FGF-2 and Ang-1 production 
in β1 cells was not changed on smooth TCPS, PT or SLA substrates but was significantly 
increased on microrough, hydrophilic modSLA substrates (Figure 3-4D,E).  Secreted 
levels of FGF-2 by  β1 silenced cells were similar to levels in MG63 cells on all substrates 
(Figure 3-4D).  Ang-1 production on modSLA substrates was significantly  higher in β1 
silenced cell cultures compared to MG63 cells (Figure 3-4E).
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Figure 3-2. Integrin α2 silenced cell response to Ti substrate features.  (A) Total cell 
number of integrin α2 silenced cells and MG63 cells were counted.  (B) Osteocalcin, (C) 
VEGF-A, (D) FGF-2, and (E) Ang-1 levels in the conditioned media of both MG63 cells 
and integrin α2 silenced MG63 cells were determined. Values presented are mean + 
SEM of six independent cultures.  Data were analyzed using ANOVA and statistical 
significance between groups was determined using Bonferroniʼs modification of 
Studentʼs t-test. *p<0.05 vs. TCPS; #p<0.05 vs. MG63 cultures.
74
Figure 3-3. Integrin α5 silenced cell response to Ti substrate features.  (A) Total cell 
number of integrin α5 silenced cells and MG63 cells were counted.  (B) Osteocalcin, (C) 
VEGF-A, (D) FGF-2, and (E) Ang-1 levels in the conditioned media of both MG63 cells 
and integrin α5 silenced MG63 cells were determined. Values presented are mean + 
SEM of six independent cultures.  Data were analyzed using ANOVA and statistical 
significance between groups was determined using Bonferroniʼs modification of 
Studentʼs t-test. *p<0.05 vs. TCPS; #p<0.05 vs. MG63 cultures.
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Figure 3-4. Integrin β1 silenced cell response to Ti substrate features.  (A) Total cell 
number of integrin β1 silenced cells and MG63 cells were counted.  (B) Osteocalcin, (C) 
VEGF-A, (D) FGF-2, and (E) Ang-1 levels in the conditioned media of both MG63 cells 
and integrin β1 silenced MG63 cells were determined. Values presented are mean + 
SEM of six independent cultures.  Data were analyzed using ANOVA and statistical 
significance between groups was determined using Bonferroniʼs modification of 
Studentʼs t-test. *p<0.05 vs. TCPS; #p<0.05 vs. MG63 cultures.
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3.4 Discussion
Integrin binding to titanium substrates is important in triggering osteoblastic 
differentiation of cells in response to surface microstructure and energy.  A number of 
integrins have been identified as being involved in osteoblast attachment and 
differentiation [28, 29].  In the present study, we found that knockdown of specific integrin 
subunits in an MG63 osteoblast-like cell line not only  affects the differentiation of these 
cells in response to Ti surface topography and energy, but also affects the production of 
pro-angiogenic growth factors.
We found that the expression of integrin receptor subunits involved in 
osteoblastic differentiation is affected in response to Ti surface features.  Our results are 
consistent with those found previously  where expression of integrins α2 and β1 are 
increased on rough Ti surfaces and expression of integrin α5 is decreased [10, 18]. 
Similar to integrins α2 and β1, we observed that expression of integrin α1 is increased on 
microrough Ti surfaces compared to smooth Ti and TCPS control surfaces.  
Cells cultured on Ti substrates presenting a rough surface morphology  and high 
surface energy  have a more differentiated phenotype displaying increased levels of 
osteocalcin, osteoprotegerin, and the local factor prostaglandin E2 [26].  Knockdown of 
either the α2 or β1 integrin subunits in these cells resulted in the loss of differentiation in 
response to Ti surface microstructure [18, 19] whereas knockdown of the α5 subunit did 
not result in any  significant changes in the differentiation of MG63 osteoblast-like cells
[30]. 
The mechanism by which Ti surface microstructure and energy  regulate the 
production of pro-angiogenic growth factors by  osteoblasts is unclear.  We found here 
that knockdown of several integrin receptor subunits differentially  regulated the 
production of VEGF-A, FGF-2, and Ang-1.  In particular, secreted levels of VEGF-A were 
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increased in cells silenced for integrins α2, α5, and β1 whereas silencing of integrin α1 
resulted in a decrease in VEGF-A production in response to Ti surface topography  and 
energy.  Levels of FGF-2 were only  affected in response to knockdown of either α1 or α2, 
and were decreased on modSLA Ti surfaces in these cells.  In contrast, secretion of 
Ang-1 was increased on modSLA Ti surfaces in α1, α2, and β1 silenced cells compared 
to wild-type MG63 cells.  Taken together, these results suggest that signaling events 
through integrin adhesion receptors may regulate the production of pro-angiogenic 
growth factors to induce endothelial cell migration and subsequent vascular formation 
during peri-implant healing.
Integrin α5β1 binds fibronectin [5] and has been suggested to promote early 
osteoblast proliferation and differentiation events and shRNA targeting endogenous 
integrin α5 has been found to inhibit osteoblastic differentiation of mesenchymal stromal 
cells [31], potentially explaining why α5 silencing did not have a largely significant effect 
on the expression of osteogenic or angiogenic markers in MG63 cells.  Both α1β1 and 
α2β1 bind collagen I in the extracellular matrix [32] and both integrin receptors recognize 
and bind the same GFOGER motif [33].  However, in our study we found that silencing of 
the α1 integrin subunit resulted in a decrease in the production of VEGF-A by MG63 cells 
in response to Ti surface features while knockdown of the α2 integrin subunit increased 
VEGF-A production.  This data suggests that activation of the α1β1 integrin is necessary 
for the production of VEGF-A in MG63 osteoblast like cells whereas α2β1 integrin binding 
and activation serves to downregulate VEGF-A expression.  This may indicate that 
downstream signaling events differ between α1β1 and α2β1 integrins, resulting in the 
different effects induced by knockdown of each integrin.
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Overall, our results indicate that in addition to promoting differentiation, signaling 
through integrin receptor complexes regulates the angiogenic response of osteoblasts to 
implant surface features.  Further examination of the effect of conditioned media from 
knockdown cell cultures is necessary to determine if the differences in production of 
these growth factors influences endothelial cell differentiation.  Also, it is possible that 
signaling events through other integrin adhesion receptors such as αv and β3 may 
modulate the production of angiogenic growth factors by osteoblasts. 
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CHAPTER 4.  The Role of VEGF-A in Cell Response to Titanium 
Surface Microstructure and Energy
4.1  Introduction
! The surface properties of biomaterials directly  influence the attachment, 
proliferation, and phenotypic expression of cells both in vitro and in vivo [1-5].  The first 
events after implantation of a material into the body  involve the adsorption of proteins 
onto the surface of the material from the surrounding blood and tissue fluid [REF].  The 
topography, chemistry, and energy  of a biomaterial surface are all known to affect this 
process and the subsequent cellular response.
! In orthopaedics and dentistry, titanium (Ti) is a commonly  used material due to its 
biocompatibility, good mechanical properties and resistance to wear.  The 
biocompatibility  and wear resistance of Ti is due to the thin oxide layer (TiO2) that forms 
on its surface.  Substrates fabricated from commercially  pure Ti can be used to assess 
osteoblast response in vitro and bone formation in vivo.  It is well known that Ti 
substrates presenting a rough micron-scale topography  affect the attachment and 
differentiation of osteoblasts in vitro [6].  Cells cultured on these substrates display  a 
more differentiated phenotype with a reduction in proliferation and an increase in the 
production of factors that generate an osteogenic microenvironment, including 
osteocalcin, PGE2, TGFβ1, and osteoprotegerin [7].  Combining a rough surface 
microtopography with a high surface energy  further enhances the differentiation of 
osteoblasts on Ti surfaces [8].  Rough Ti substrates support greater bone to implant 
contact and have higher torque removal strengths in vivo [9, 10].
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! In addition to promoting osteoblast differentiation and bone formation, the 
establishment of a vascular supply  is of critical importance in orthopaedic and dental 
applications.  Angiogenesis, the sprouting of new capillary  blood vessels from the pre-
existing vasculature, is an important part of bone formation and bone fracture healing 
[11].  Vascularization of the cartilage template precedes ossification during both 
intramembranous and endochondral ossification [12-14].  Bone remodeling, 
regeneration, and osseintegration of implanted biomaterials is also dependent on the 
delivery of osteoprogenitor cells via a vascular supply [15, 16].  
! Osteoblast and osteoblast progenitor cells have been demonstrated to produce 
and secrete several pro-angiogenic growth factors, including vascular endothelial growth 
factor-A (VEGF-A), basic fibroblast growth factor (FGF-2), and angiopoietin-1 (Ang-1), 
and that the expression of these growth factors is dependent on the state of maturation 
of the cell [17-20].  Further, we and others have also found that the expression of these 
growth factors is dependent on Ti surface microtopography and energy [21-23].!
! VEGF-A has been identified as a particularly  important growth factor during bone 
formation and remodeling.  VEGF-A is a member of the VEGF family  of proteins that 
include VEGF members -A, -B, -C, -D, and PlGF-1 and -2.  These growth factors all 
have the ability  to stimulate endothelial cell proliferation and differentiation [24, 25]. 
VEGF-A is expressed by  hypertrophic chondrocytes and may  be involved directly in 
osteoblast differentiation [26, 27].
! VEGF-A exerts its effects through two tyrosine kinase receptors, VEGFR1/Flt-1 
and VEGFR2/KDR.  Both VEGF receptors have been found to be expressed by 
osteoblasts during their differentiation [17, 28, 29].  
! While it is known that osteoblasts express VEGF-A and the receptors for VEGF-A 
and that disruption of VEGF-A signaling in osteoblasts inhibits bone formation during 
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endochondral ossification, it is not known whether VEGF-A production by  osteoblasts in 
response to Ti surface microtopography  and energy  has an effect on the differentiation of 
these cells.  In the present study, we sought to determine the potential role that VEGF-A 
has in mediating the differentiation of osteoblasts to Ti surface microtopography  and 
energy.  To do this, we stably  silenced VEGF-A in an MG63 osteoblast-like cell line using 
shRNA targeting VEGF-A.  We cultured wild-type MG63 cells and VEGF-A silenced 
MG63 cells on Ti surfaces presenting different surface roughness and energy  and 
examined the production of osteogenic and angiogenic growth factors in these cells.  To 
determine if VEGF-A produced by MG63 cells has a paracrine effect on endothelial cells, 
we used conditioned media from wild-type MG63 and VEGF-A silenced MG63 cell 
cultures in an in vitro fibrin gel assay  to assess endothelial tubule formation.  To see if 
endogenous VEGF-A produced by  MG63 cells in response to Ti surface roughness and 
energy  has an autocrine effect on MG63 cell differentiation through interaction with 
VEGFR2/Flk-1, we used a monoclonal antibody  against human VEGFR2/Flk-1 in wild-
type MG63 cell cultures on Ti substrates.  We also treated MG63 cells on Ti surfaces 
with rhVEGF-A or rhFGF-2 to determine if osteoblastic differentiation is enhanced with 
treatment of either of these growth factors.  Finally, to see if the production of osteogenic 
and angiogenic growth factors in VEGF-A silenced MG63 cells could be restored to wild-
type levels, we treated VEGF-A silenced MG63 cells with exogenous rhVEGF-A or 
rhFGF-2.
4.2  Materials & Methods
4.2.1 Preparation of Ti substrates
! Ti disks were prepared from 1 mm thick sheets of grade 2 unalloyed 
commercially  pure Ti punched into 15mm diameter disks and supplied by  Institut 
Straumann AG (Basel, Switzerland).  The production and characterization of smooth 
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pretreatment (PT), sand blasted and acid etched (SLA), and modified SLA (modSLA) 
surfaces have been described previously  [8].  PT surfaces were degreased by washing 
Ti disks in acetone and processed in a 2%  ammonium fluoride/2%  hydrofluoric acid/10% 
nitric acid solution.  SLA surfaces were made by coarse grit-blasting of the PT surfaces 
with 0.25-0.50 mm corundum grit followed by  acid etching.  modSLA surfaces were 
made using the same procedure as SLA surfaces under nitrogen rinsing to prevent 
exposure to air and were then stored under aqueous conditions  under nitrogen to retain 
high surface free energy.  The PT surface has an overall average roughness (Ra) of less 
than 0.7 µm.  SLA and modSLA surfaces have a complex microtopography  with craters 
varying from 30 to 100 µm in diameter overlaid with pits from 1 to 3 µm in diameter.  The 
acid etch creates sharp edges approximately  700 nm in height, resulting in an overall Ra 
of approximately 4 µm.  PT, SLA and modSLA Ti disks all have a TiO2 surface layer, with 
the PT and SLA surfaces being hydrophobic due to the adsorption of atmospheric 
hydrocarbons while the modSLA surface is hydrophilic.  Advancing contact angles were 
used to calculate the hydrophilicity  of the surfaces as PT (95.8o), SLA (139.80o), and 
modSLA (~0o).  Surface free energy  for PT, SLA, and modSLA surfaces was calculated 
according to Zisman (critical surface tension), Equation of State (EOS), and Geometric 
Mean approaches and is described in detail elsewhere [30].
4.2.2 General Cell Culture
! MG63 osteoblast-like osteosarcoma cells were maintained in culture using 
Dulbeccoʼs Modified Eagleʼs Medium (DMEM) supplemented with 10% fetal calf serum 
and 1% penicillin/streptomycin.  Stably  silenced MG63 cells for VEGF-A were cultured in 
DMEM containing 10% fetal calf serum, 1% penicillin/streptomycin and 0.5 µg/mL 
puromycin for selection of successfully  transduced cells.  For experiments, both MG63 
cells and VEGF-A silenced MG63 cells were plated at an initial seeding density of 
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10,000 cells/cm2 in 24-well standard tissue culture plates.  Media were changed 24 
hours after plating and every 48 hours thereafter until the cells were 100% confluent. 
When cells reached 100% confluent on TCPS, media from all cultures were collected 
and examined for secreted levels of VEGF-A, FGF-2, Ang-1, OPG, and osteocalcin 
where appropriate.  
! Human aortic endothelial cells (HAEC), for use in endothelial tubule formation 
assays, were maintained in culture using Endothelial Cell Growth Medium-2 (EGM-2, 
Lonza, Walkersville, MD).  For experiments, HAEC were plated at a density  of 5,000 
cells/cm2 on fibrin gel coated 96-well plates as described in detail in section 4.2.11.
4.2.3 Generation of VEGF-A silenced MG63 cells
! To generate stably  silenced MG63 cells for VEGF-A, we used MISSION® shRNA 
lentiviral transduction particles targeting the VEGF-A gene (Sigma-Aldrich, St. Louis, 
MO).   5 separate shRNA clones were designed and packaged into self-inactivating 
replication incompetent lentiviral particles for transduction.  The sequences for the 5 











In additioned to the 5 clones described above, an empty shRNA vector, not containing a 
hairpin insert (PLK0.1) and an shRNA sequence not targeting any gene in the human 
genome (NT) were used as controls.  
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! To transduce cells, MG63 cells were plated at a density of 10,000 cells/cm2.  After 
reaching 60 – 70% confluency, cells were transduced with lentiviral particles at a 
multiplicity of infection (MOI) of 5.  After 18 hours, media containing lentiviral particles 
were discarded into a bleach solution and cells were fed with DMEM containing 10% 
fetal calf serum and 1% penicillin/streptomycin.  The following day, 0.5 µg/mL puromycin 
were added to transduced MG63 cell cultures to select for successfully transduced cells.  
Transduced cells were maintained in medium containing 0.5 µg/mL puromycin until 
plating for experiments.
4.2.4 Flk-1/IgG Antibody Treatment
! MG63 cells plated on tissue culture polystyrene (TCPS, control for all studies), 
PT, SLA, and modSLA Ti substrates were treated with 100 ng/mL of an Flk-1 mouse anti-
human monoclonal neutralization antibody  (R&D Systems, Minneapolis, MN) or 100 ng/
mL of a rabbit anti-human nonspecific IgG polyclonal antibody (NeoMarkers, Fremond, 
CA) for the duration of cell culture.
4.2.5 rhVEGF-A Treatment
! For studies examining the effect of addition of exogenous VEGF-A to cells on Ti 
substrates, cell culture media were supplemented with 20 ng/mL rhVEGF-A165 (R&D 
Systems, Minneapolis, MN) and MG63 cells and VEGF-A silenced MG63 cells were 
treated with VEGF-A supplemented media for the duration of cell culture.
4.2.6 rhFGF-2 Treatment
! For studies examining the effect of addition of exogenous FGF-2 to cells on Ti 
substrates, cell culture media were supplemented with 10 ng/mL rhFGF-2 (R&D 
Systems, Minneapolis, MN) and MG63 cells and VEGF-A silenced MG63 cells were 
treated with FGF-2 supplemented media for the duration of cell culture.
4.2.7 Cell Number
88
Total cell number were determined for all cell types and treatments at time of 
harvest.  At confluence, cells were released from TCPS and Ti surfaces using two 
sequential incubations with 0.25%  trypsin for 10 minutes at 37oC to ensure that no cells 
remained on the rough Ti surfaces and counted using an automated cell counter (Z1 
Particle counter, Beckman Coulter, Fullerton, CA).
4.2.8 Alkaline Phosphatase Specific Activity
Alkaline phosphatase specific activity  (orthophosphoric monoester 
phosphohydrolase, alkaline; E.C. 3.1.3.1) was measured in the cell lysates as a marker 
of osteoblastic differentiation.  Enzyme activity  was determined using a colorimetric 
assay measuring the release of p-nitrophenol from p-nitrophenylphosphate at 37oC. 
Samples were read on a plate reader at 415nm [39].
4.2.9 Osteocalcin
Osteocalcin levels in the conditioned medium of MG63 cells and VEGF-A 
silenced MG63 cells grown on Ti surfaces were determined as a marker of osteoblast 
maturation using a commercially  available radioimmunoassay (Biomedical Technologies, 
Inc., Stoughton, MA) following the manufacturerʼs protocol.
4.2.10 VEGF-A, FGF-2, Ang-1, OPG
Secreted levels of VEGF-A, FGF-2, Ang-1, and OPG by MG63 cells and VEGF-
A silenced MG63 cells were determined in the conditioned medium using commercially 
available ELISA assays (Duoset ELISA Development Systems, R&D Systems, 
Minneapolis, MN) following the manufacturerʼs protocols.
4.2.11 Endothelial Cell Differentiation
To determine if the conditioned media were angiogenic, we examined their ability 
to support endothelial tubule formation using a fibrin gel assay  (Millipore, St. Charles, 
MO).  Briefly, each well of a 96-well tissue culture plate were coated with 30 µL of a 
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fibrinogen solution and 20 µL of a thrombin solution and the mixture was allowed to 
polymerize for at least 1 hour at 37oC.  HAECs were plated in 100 µL of EGM-2 at a 
density  of 5 x 103 cells/well and cultured at 37oC for 24h.  At 24h, media were removed 
and a second layer of fibrin was added on top of cells by  again mixing 30 µL of 
fibrinogen and 20 µL of thrombin.  The mixture was allowed to polymerize for 5 minutes 
before 100 µL of conditioned media from either MG63 cell cultures or VEGF-A silenced 
MG63 cell cultures on TCPS, PT, SLA, or modSLA substrates were added.  At 12, 24, 
and 36 after the addition of conditioned media, images were taken for morphometric 
analysis to determine total endothelial tube length.
4.2.12 Real-time Reverse Transcriptase Polymerase Chain Reaction
! Real-time RT-PCR for human VEGF-A and human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were run to test for silencing efficiency  of VEGF-A in 
transduced MG63 cell cultures.  Briefly, RNA was isolated from confluent cultures of 
wild-type MG63 cells, H1-H5 transduced MG63 cells, and NT and PLK0.1 transduced 
MG63 cells using Trizol (Invitrogen).  RNA was quantified using a Nanodrop 
spectrophotometer (Thermo Scientific, Waltham, MA).  mRNA quantities were assessed 
for both VEGF-A and GAPDH using the primers outlined below.
VEGF-A Forward - CTTGCCTTGCTGCTCTACC
VEGF-A Reverse – TTCTGCCCTCCTCCTTCTG
GAPDH Forward - GCTCTCCAGAACATCATCC
GAPDH Reverse – TGCTTCACCACCTTCTTG
To create a cDNA template, 1 µg of RNA was reverse transcribed using random primers 
(Promega, Madison, WI) and Omniscript reverse transcriptase (Qiagen, Valencia, CA). 
Quantification of VEGF-A and GAPDH genes was done using real-time qPCR using 
SYBR Green as a fluorescent marker.  Fluorescence values were quantified as starting 
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quantities using known dilutions of MG63 cell RNA.  VEGF-A mRNA levels were 
normalized to expression of GAPDH for all cell types.
4.2.13 Statistical Analysis
The data presented here are from one of at least two separate sets of 
experiments.  Both sets of experiments yielded comparable observations.  For any  given 
experiment, each data point represents the mean + standard error of six individual 
cultures.  Data were analyzed by  ANOVA and when statistical differences were detected, 
Studentʼs t-test for multiple comparisons using Bonferroniʼs modification was used.  p-
values < 0.05 were considered significant.
4.3 Results
4.3.1 Flk-1 antibody treatment
! We have previously  shown that MG63 osteoblast-like cells secrete higher levels 
of VEGF-A on SLA and modSLA Ti substrates compared to TCPS and smooth PT Ti 
substrates[22].  It has also been reported that osteoblasts express the VEGF receptor 
Flk-1/KDR (VEGFR2)[17, 27].  In order to determine if VEGF-A produced by  MG63 cells 
has an autocrine effect, we added an Flk-1 neutralization antibody  to MG63 cell cultures 
on TCPS and Ti substrates.  Consistent with previous results, total cell number in MG63 
cell cultures were reduced on microrough SLA substrates, and microrough, hydrophilic 
modSLA surfaces compared to TCPS.  Addition of either Flk-1 neutralization antibody or 
nonspecific IgG antibody had no effect on cell number (Figure 4-1A).  Alkaline 
phosphatase specific activity  in MG63 cells were unchanged amongst any of the 
surfaces examined and addition of either Flk-1 neutralization antibody or IgG control 
antibody  had no effect on alkaline phosphatase specific activity  (Figure 4-1B).  Secreted 
levels of osteocalcin, a late marker of osteoblast differentiation, were significantly 
increased (p<0.05) in MG63 cells cultured on SLA and modSLA surfaces compared to 
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TCPS substrates while the addition of either antibody had no effect on osteocalcin levels 
compared to MG63 cells (Figure 4-1C).  Osteoprotegerin (OPG) secretion by MG63 cells 
were similar on TCPS and smooth PT Ti substrates.  Addition of a rough surface 
microarchitecture observed on SLA substrates had no effect on secreted levels of OPG 
by  MG63 cells.  However, on rough, hydrophilic, modSLA substrates, OPG levels were 
significantly  increased.  Addition of either an Flk-1 neutralization antibody  or nonspecific 
IgG antibody had no effect on OPG levels compared to MG63 cells (Figure 4-1D).
! Consistent with what we have found previously, production of VEGF-A by  MG63 
cells was significantly increased on both SLA and modSLA substrates compared to 
TCPS and smooth PT surfaces.  Addition of an Flk-1 neutralization antibody  to MG63 
cell cultures significantly  increased production of VEGF-A on all surfaces compared to 
MG63 cells with no antibody, with the largest increase occurring on modSLA substrates. 
A nonspecific IgG antibody had no effect on VEGF-A production versus MG63 cell 
cultures (Figure 4-2A).  FGF-2 production by  MG63 cells was not changed in response 
to treatment with either an Flk-1 neutralization antibody or a nonspecific IgG antibdody, 
however a surface roughness and energy  dependent increase in FGF-2 production was 
observed in all three treatment groups (Figure 4-2B).  Angiopoietin-1 levels were 
unaffected by treatment with either antibody or by any surface type tested (Figure 4-2C).
4.3.2 VEGF-A silencing
! To verify  successful silencing of VEGF-A in MG63 cells, we examined both the 
total secreted protein levels in the conditioned media and VEGF-A gene expression 
using real-time reverse transcriptase polymerase chain reaction (RT-qPCR) for the five 
shRNA sequences for human VEGF-A as well as a scrambled shRNA sequence (NT) 
and an empty  vector (PLK0.1).  VEGF-A protein levels in MG63 cells, NT, and PLK0.1 
cell lines were comparable to each other.  VEGF-A shRNA clones H1-H5 secreted 
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varying levels of VEGF-A into the conditioned media as outlined in table 4-1 below and 
Figure 4-3A.  Notably, clone H4 showed the largest reduction in VEGF-A protein levels, 
with a 94.1% reduction in VEGF-A compared to MG63 cells.
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Figure 4-1.  Response of MG63 cells cultured on TCPS and Ti surfaces in the presence 
an Flk-1 neutralizing antibody.  (A) Cell Number, (B) Alkaline phosphatase specific 
activity  in the cell lysate, (C) osteocalcin, and (D) osteoprotegerin levels in the 
conditioned media. Cells were cultured on control (TCPS), PT, SLA, and modSLA Ti 
surfaces.  Values presented are mean + SEM of six independent cultures.  The data 
presented are from one of two separate experiments with comparable results.  Data 
were analyzed using ANOVA and statistical significance between groups was 
determined using Bonferroniʼs modification of Studentʼs t-test.  *p< 0.05 vs. TCPS.
94
Figure 4-2.  Production of angiogenic growth factors by  MG63 cells cultured in the 
presence of an Flk-1 neutralizing antibody.  (A) VEGF-A, (B) FGF-2, and (C) 
angiopoietin-1 levels in the conditioned media. Cells were cultured on control (TCPS), 
PT, SLA, and modSLA Ti surfaces.  Values presented are mean + SEM of six 
independent cultures.  The data presented are from one of two separate experiments 
with comparable results.  Data were analyzed using ANOVA and statistical significance 
between groups was determined using Bonferroniʼs modification of Studentʼs t-test. 
*p<0.05 vs. TCPS ; #p<0.05 vs. MG63.
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Table 4-1:  VEGF-A Protein Levels






! To further verify  silencing, real-time PCR gene expression for VEGF-A was done. 
Similar to VEGF-A protein levels, VEGF-A gene expression levels for MG63 cells, NT, 
and PLK0.1 vectors were similar, while the VEGF-A shRNA clones H1-H5 had varying 
levels of expression compared to MG63 cells (Table 4-2 and Figure 4-3B).  
Table 4-2:  VEGF-A Gene Expression






! Based on the results of VEGF-A protein and gene expression levels in shRNA 
transduced MG63 cells, we selected clone H4 for further experiments.  Based on the 
results observed for VEGF-A at both the gene and protein level where no difference in 
expression was found in response to transduction with either a scrambled shRNA 
sequence or an empty  vector, it was decided that lentiviral transduction of MG63 cells 
did not have an adverse effect on cell response and thus in future experiments only  wild-
type MG63 cells and VEGF-A silenced cells obtained from clone H4 were used to reduce 
sample size.
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  To see if the reduced levels of VEGF-A produced in VEGF-A silenced cells had an 
effect on endothelial cell response, we performed an in vitro MatrigelTM endothelial cell 
tubule formation assay using conditioned media from either MG63 cells or VEGF-A 
silenced MG63 cells.   Total endothelial tubule length was reduced at 4, 8, and 12 hours 
after the addition of conditioned media from either MG63 cells or VEGF-A silenced 
MG63 cells (Figure 4-3C).
! We next examined the effect of VEGF-A silencing on cell response to Ti substrate 
microtopography and surface energy.  Consistent with previous results, total cell number 
was reduced on SLA and modSLA Ti surfaces in MG63 cell cultures compared to TCPS 
and smooth PT Ti surfaces.  Cell number in VEGF-A silenced MG63 cells were 
comparable to that observed in wild-type MG63 cells on all surfaces examined (Figure 
4-4A).  Alkaline phosphatase specific activity  in MG63 cells were unchanged in response 
to surface microtopography  and surface energy.  In VEGF-A silenced MG63 cells, levels 
of alkaline phosphatase specific activity  were significantly  reduced on TCPS and PT 
surfaces compared to MG63 cell cultures.  Alkaline phosphatase levels were also 
reduced in VEGF-A silenced cell cultures on SLA and modSLA Ti surfaces compared to 
MG63 cell cultures, though these reductions were not statistically significant (Figure 
4-4B).  Secreted levels of both osteocalcin and osteoprotegerin showed surface 
roughness and energy dependent increases in MG63 cell cultures.  Silencing of VEGF-
A in MG63 cells significantly  reduced secreted levels of both growth factors, though 
surface roughness and energy dependent increases were still observed (Figure 4-4C,D).  
! VEGF-A levels were reduced by  greater than 80% on all surfaces in VEGF-A 
silenced MG63 cells (Figure 4-5A).  Silencing of VEGF-A in MG63 cells affected the 
production of FGF-2 and Ang-1.  Production of FGF-2 by  MG63 cells were increased in 
response to surface microtopography.  Addition of high surface free energy  further 
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increased production of FGF-2, consistent with previous results [Raines].  In VEGF-A 
silenced cell cultures, FGF-2 levels were only  reduced with the combination of surface 
microtopography and energy seen on modSLA substrates (Figure 4-5B).  Angiopoietin-1 
levels were unaffected by  either surface roughness or energy  in both MG63 cells and 
VEGF-A silenced MG63 cells, though levels in VEGF-A silenced MG63 cells were 
reduced by at least 50% on all surfaces (Figure 4-5C).
98
Figure 4-3.  Verification of VEGF-A silencing in an MG63 cell line using lentiviral-
mediated transduction of shRNA specific for human VEGF-A.  (A) VEGF-A protein 
levels, and (B) VEGF-A mRNA levels were determined in 5 separate MG63 cell lines 
established using shRNA sequences specific for VEGF-A as well as a scrambled 
shRNA sequence (NT) and an empty  vector control (PLK0.1).  *p<0.05 vs. MG63.  (C) 
Total endothelial tube length in the presence of conditioned media from MG63 cells and 
VEGF-A silenced clone H4 cells.  *p<0.05 vs. 4h; #p<0.05 vs. MG63.
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Figure 4-4.  Response of MG63 and VEGF-A silenced MG63 cells cultured on TCPS 
and Ti surfaces.  (A) Cell Number, (B) alkaline phosphatase specific activity in the cell 
lysate, (C) osteocalcin, and (D) osteoprotegerin levels in the conditioned media. Cells 
were cultured on control (TCPS), PT, SLA, and modSLA Ti surfaces.  Values presented 
are mean + SEM of six independent cultures.  The data presented are from one of two 
separate experiments with comparable results.  Data were analyzed using ANOVA and 
statistical significance between groups was determined using Bonferroniʼs modification 
of Studentʼs t-test.  *p< 0.05 vs. TCPS ; #p<0.05 vs. MG63.
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Figure 4-5.  Angiogenic response of MG63 cells and VEGF-A silenced MG63 cells 
cultured on TCPS and Ti substrates.  (A) VEGF-A, (B) FGF-2, and (C) angiopoietin-1 
levels in the conditioned media. Cells were cultured on control (TCPS), PT, SLA, and 
modSLA Ti surfaces.  Values presented are mean + SEM of six independent cultures. 
The data presented are from one of two separate experiments with comparable results. 
Data were analyzed using ANOVA and statistical significance between groups was 
determined using Bonferroniʼs modification of Studentʼs t-test.  *p<0.05 vs. TCPS  ; 
#p<0.05 vs. MG63.
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4.3.3 Endothelial cell differentiation
! Conditioned media from MG63 cell cultures and VEGF-A silenced MG63 cell 
cultures were used to assess endothelial cell tubule formation in a fibrin gel assay.  At 
12, 24, and 36 hours after the addition of conditioned media, total endothelial tube length 
were increased on SLA and modSLA surfaces compared to TCPS and smooth PT 
surfaces in MG63 cells.  However, in VEGF-A silenced cell cultures, no increase in 
endothelial tubule formation was observed in response to surface roughness or energy 
(Figure 4-6A,B).  Further, 36 hours after the addition of conditioned media, the total 
endothelial tubule length in cells treated with media from VEGF-A silenced MG63 cell 
cultures compared to cells treated with media from MG63 cells were significantly 
reduced on all surfaces (Figure 4-6C).
4.3.4 rhVEGF-A treatment
! To see if the response of VEGF-A silenced MG63 cells to Ti surface 
microtopography and energy  could be restored, we treated MG63 cells and VEGF-A 
silenced MG63 cells with 20 ng/mL rhVEGF-A165.  Total cell number was reduced in 
response to surface topography and energy for all groups.  Treatment with rhVEGF-A165 
had no effect on cell number in either MG63 cells or VEGF-A silenced MG63 cells 
compared to untreated controls (Figure 4-7A).  Alkaline phosphatase specific activity  in 
MG63 cells were increased only  on modSLA surfaces.  Treatment of MG63 cells with 
rhVEGF-A165 had no effect on alkaline phosphatase specific activity  in response to either 
surface topography  or energy and was unchanged compared to untreated MG63 cells. 
In VEGF-A silenced MG63 cells and in VEGF-A silenced MG63 cells treated with 
rhVEGF-A165, alkaline phosphatase specific activity  was significantly  reduced on all 
surfaces examined relative to MG63 cell cultures (Figure 4-7B).!
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Figure 4-6.  Endothelial tubule formation in response to VEGF-A silenced cell cultures. 
Media from MG63 cell cultures and VEGF-A silenced cell cultures on control (TCPS), PT, 
SLA, and modSLA Ti substrates were used to assess endothelial cell differentiation 
using a fibrin gel endothelial tubule formation assay.  Total endothelial cell tube length 
was determined morphometrically  at (A) 12 hours, (B) 24 hours, and (C) 36 hours after 
seeding of endothelial cells onto fibrin gel coated 96-well plates in the presence of 
conditioned media.  *p<0.05 vs. TCPS; #p<0.05 vs. MG63.
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Figure 4-7.  MG63 and VEGF-A silenced cell response to treatment with exogenous 
rhVEGF-A165.  (A) Cell number and (B) alkaline phosphatase specific activity  in the cell 
lysate was determined for both MG63 and VEGF-A silenced MG63 cells as well as 
MG63 and VEGF-A silenced MG63 cells treated with 20 ng/mL of rhVEGF-A165. Values 
presented are mean + SEM of six independent cultures. Data were analyzed using 
ANOVA and statistical significance between groups was determined using Bonferroniʼs 
modification of Studentʼs t-test. *p<0.05 vs. TCPS; ^p<0.05 vs. MG63; #p<0.05 vs. no 
rhVEGF-A treatment.
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Osteocalcin and osteoprotegerin levels were similar on control TCPS and smooth PT 
surfaces in MG63 cells.  On microrough SLA and hydrophilic, microrough modSLA 
surfaces, levels of both osteocalcin and osteprotegerin were significantly  increased 
against control TCPS cultures (Figure 4-8A,B).  Similar to our earlier results, levels of 
osteocalcin and osteoprotegerin in VEGF-A silenced MG63 cell cultures displayed a 
surface roughness and energy  dependent increase but were significantly  reduced 
compared to MG63 cell cultures on all surfaces examined.  Treatment of VEGF-A 
silenced MG63 cells with rhVEGF-A165 increased osteocalcin levels to those 
comparable to MG63 cell cultures on all substrates.  However, levels of osteoprotegerin 
were only  increased in rhVEGF-A165 treated VEGF-A silenced cells on modSLA 
surfaces (Figure 4-8A,B).
! Treatment of MG63 cells and VEGF-A silenced MG63 cells with rhVEGF-A had 
an effect on the production of angiogenic growth factors in response to surface 
topography  and energy.  Secreted levels of FGF-2 were similar amongst all groups on 
TCPS, PT, and SLA surfaces.  The combination of a rough surface microtopgraphy and 
high surface free energy  observed on modSLA surfaces increased FGF-2 production in 
MG63 cells.  Treatment of MG63 cells with rhVEGF-A displayed a further, modest 
increase in FGF-2 production compared to untreated cells, though this increase was not 
statistically  significant (Figurre 4-9A).  In VEGF-A silenced MG63 cells, FGF-2 
production was significantly  reduced compared to MG63 cells and treatment with 
rhVEGF-A165 increased FGF-2 production to levels comparable to wild-type MG63 cell 
cultures (Figure 4-9A).  Ang-1 levels were unchanged in response to surface 
microtopgraphy and surface energy  in both MG63 cells and VEGF-A silenced MG63 
cells, though levels in VEGF-A silenced MG63 cells were significantly  reduced. 
Treatment with rhVEGF-A165 had no effect on Ang-1 production in response to surface 
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topography.  However, on modSLA surfaces, levels of Ang-1 in both MG63 cells and 
VEGF-A silenced MG63 cells were significantly  increased compared to control TCPS 
cultures.  In addition, levels of Ang-1 in rhVEGF-A165 treated VEGF-A silenced MG63 
cells were comparable to those observed in wild-typeMG63 cells (Figure 4-9B).
4.3.5 rhFGF-2 treatment
! Since endogenous knockdown of VEGF-A in MG63 cells resulted in a decrease 
in the production of FGF-2 in response to Ti surface microtopography  and energy, we 
treated VEGF-A silenced MG63 cells with exogenous rhFGF-2 to see if FGF-2 was 
mediating MG63 cell response to Ti surface properties.  In MG63 cells, treatment with 10 
ng/mL rhFGF-2 resulted in a significant increase in total cell number at time of harvest 
against untreated MG63 cells on all surfaces examined (Figure 4-10A).  On control 
TCPS surfaces, VEGF-A silenced MG63 cells treated with rhFGF-2 displayed an 
increase in cell number compared to untreated VEGF-A silenced MG63 cells.  However, 
treatment with rhFGF-2 did not have any  effect on cell number in response to Ti surface 
topography  or energy  (Figure 4-10A).  In both MG63 cells and VEGF-A silenced MG63 
cells, alkaline phosphatase specific activity  were increased compared to untreated 
control cells on control TCPS, smooth PT and SLA Ti surfaces.  Further, an increase in 
alkaline phosphatase specific activity  in response to rhFGF-2 treatment was seen on 
microrough, hydrophilic modSLA Ti surfaces in MG63 cell cultures but not in VEGF-A 
silenced MG63 cell cultures.  In all cell types examined, surface topography and energy 
had no effect on alkaline phosphatase specific activity (Figure 4-10B).
!
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Figure 4-8. MG63 and VEGF-A silenced cell response to treatment with exogenous 
rhVEGF-A 165. (A) Osteocalcin and (B) osteoprotegerin levels in the conditioned media 
were determined for both MG63 and VEGF-A silenced MG63 cells as well as MG63 and 
VEGF-A silenced MG63 cells treated with 20 ng/mL of rhVEGF-A165. Values presented 
are mean + SEM of six independent cultures. Data were analyzed using ANOVA and 
statistical significance between groups was determined using Bonferroniʼs modification 
of Studentʼs t-test. *p<0.05 vs. TCPS; ^p<0.05 vs. MG63; #p<0.05 vs. no rhVEGF-A 
treatment.
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Figure 4-9. MG63 and VEGF-A silenced cell response to treatment with exogenous 
rhVEGF-A 165. (A) FGF-2 and (B) angiopoietin-1 levels in the conditioned media were 
determined for both MG63 and VEGF-A silenced MG63 cells as well as MG63 and 
VEGF-A silenced MG63 cells treated with 20 ng/mL of rhVEGF-A165. Values presented 
are mean + SEM of six independent cultures. Data were analyzed using ANOVA and 
statistical significance between groups was determined using Bonferroniʼs modification 
of Studentʼs t-test. *p<0.05 vs. TCPS; ^p<0.05 vs. MG63; #p<0.05 vs. no rhVEGF-A 
treatment.
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Figure 4-10. MG63 and VEGF-A silenced cell response to treatment with exogenous 
rhFGF-2. (A) Cell number and (B) alkaline phosphatase specific activity  in the cell lysate 
was determined for both MG63 and VEGF-A silenced cells treated with or without 10 ng/
mL rhFGF-2. Values presented are mean + SEM of six independent cultures. Data were 
analyzed using ANOVA and statistical significance between groups was determined 
using Bonferroniʼs modification of Studentʼs t-test. *p<0.05 vs. TCPS; ^p<0.05 vs. MG63; 
#p<0.05 vs. no rhFGF-2 treatment.
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! We next examined whether treatment with rhFGF-2 had an effect on osteoblast 
phenotype in response to Ti surface topography  and energy.  Similar to our earlier 
results, both MG63 cells and VEGF-A silenced MG63 cells displayed a surface 
roughness and energy  dependent increase in osteocalcin and osteoprotegerin 
production, though production of these growth factors were reduced by at least 50%  in 
VEGF-A silenced MG63 cell cultures on all surfaces (Figure 4-11A,B).  Treatment with 
rhFGF-2 had no effect on the production of either osteocalcin or osteoprotegerin in either 
cell type on any surface examined (Figure 4-11A,B).
! VEGF-A levels in MG63 cells were increased in a surface roughness and energy  
dependent manner and treatment with 10 ng/mL rhFGF-2 did not have any  effect on 
production of VEGF-A in these cells.  In VEGF-A silenced cells, secreted levels of 
VEGF-A were reduced by at least 60% compared to MG63 wild-type cells on all surfaces 
and rhFGF-2 treatment did not effect secretion of this growth factor (Figure 4-12A).  For 
both cell types, Ang-1 production was unaffected by  either surface roughness or energy, 
though levels in VEGF-A silenced MG63 cells were significantly  reduced compared to 
MG63 cells and rhFGF-2 treatment also had no effect on secretion of this growth factor 
(Figure 4-12B).
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Figure 4-11. MG63 and VEGF-A silenced cell response to treatment with exogenous 
rhFGF-2. (A) Osteocalcin and (B) osteoprotegerin levels in the conditioned media were 
determined for both MG63 and VEGF-A silenced MG63 cells as well as MG63 and 
VEGF-A silenced MG63 cells treated with 10 ng/mL of rhFGF-2. Values presented are 
mean + SEM of six independent cultures. Data were analyzed using ANOVA and 
statistical significance between groups was determined using Bonferroniʼs modification 
of Studentʼs t-test. *p<0.05 vs. TCPS; ^p<0.05 vs. MG63; #p<0.05 vs. no rhFGF-2 
treatment.
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Figure 4-12. MG63 and VEGF-A silenced cell response to treatment with exogenous 
rhVEGF-A 165. (A) FGF-2 and (B) angiopoietin-1 levels in the conditioned media were 
determined for both MG63 and VEGF-A silenced MG63 cells as well as MG63 and 
VEGF-A silenced MG63 cells treated with 10 ng/mL of rhFGF-2. Values presented are 
mean + SEM of six independent cultures. Data were analyzed using ANOVA and 
statistical significance between groups was determined using Bonferroniʼs modification 




! Osseointegration of orthopaedic and dental implants is dependent not only on 
direct apposition of bone to the implant surface, but also on the formation of a patent 
vasculature in the peri-implant space to allow  delivery  of oxygen, nutrients, and cells. 
Osteoblasts are known to secrete VEGF-A, a potent endothelial cell mitogen, in 
response to a number of different stimuli, including hypoxia and several growth factors 
and hormones [31-34].  VEGF-A has also been found to have a direct role in osteoblast 
differentiation and maturation [19, 26, 27].  In the present study we show that VEGF-A 
also has a direct effect on osteoblast-like cell differentiation in response to Ti surface 
roughness and energy.
! Secreted levels of osteocalcin and osteoprotegerin, later markers of osteoblast 
differentiation, as well as levels of VEGF-A and FGF-2, two pro-angiogenic growth 
factors were increased by MG63 cells on microrough SLA and microrough, high surface 
energy  modSLA Ti substrates compared to TCPS and smooth PT Ti substrates, while 
levels of Ang-1 were unaffected by  either Ti substrate roughness or energy, consistent 
with earlier findings [22, 23, 35].  However, in VEGF-A silenced MG63 cell cultures, 
secretion of these growth factors were reduced compared to wild-type cells.  These data 
suggest that VEGF-A has an autocrine role in mediating osteoblast-like cell 
differentiation on Ti substrates in vitro.
! Addition of VEGF to fetal bovine osteoblasts increased migration and alkaline 
phosphatase expression, but had no effect on proliferation [36], while exogenous VEGF-
A165 treatment of primary  human osteoblasts increased alkaline phosphatase activity  and 
mineralized nodule formation [27].  Our results here show  that VEGF-A can enhance 
osteoblast differentiation in response to Ti surface microtopography and energy. 
Addition of 20 ng/mL rhVEGF-A165 to MG63 cells increased levels of osteocalcin and 
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osteoprotegerin as well as levels of Ang-1 and FGF-2 on microrough, high surface 
energy  modSLA surfaces, but had no effect on either cell number or alkaline 
phosphatase specific activity.  Further, in MG63 cells that have been permanently 
silenced for expression of VEGF-A, addition of exogenous VEGF-A increased secreted 
levels of osteocalcin, osteoprotegerin, FGF-2, and Ang-1 to those observed in wild-type 
MG63 cell cultures on modSLA Ti surfaces, further supporting the hypothesis that 
interaction of VEGF-A with its receptors is necessary for osteoblast maturation.
! VEGF-A exerts its effects through binding to two receptor tyrosine kinases, 
VEGFR1 (Flt1) and VEGFR2 (Flk1/KDR) that are expressed by not only  endothelial 
cells, but also chondrocytes, osteoblasts, and osteoclasts [37, 38].  In endothelial cells, 
VEGFR2 is recognized as the primary mediator of the mitogenic effects of VEGF-A 
during neo-vascularization.  Upon binding, VEGFR2 dimerizes and undergoes strong 
autophosphorylation, inducing the downstream phosphorylation of multiple proteins in 
endothelial cells, including phospholipase C-γ, PI-3 kinase, Ras, and members of the Src 
family  [39, 40].  However, a possible role for both VEGFR1 and VEGFR2 has been 
implicated in bone growth and development.
! In Flt1 (VEGFR1) null mice, trabecular bone volume and bone formation rate 
were reduced in vivo and bone marrow  stromal cell cultures from Flt1 null mice exhibited 
decreased mineralization in vitro compared to wild-type animals [41].  Interaction of 
VEGF-A with Flk1 (VEGFR2) has been demonstrated in primary human osteoblasts, and 
prostanoid mediated upregulation of VEGF-A by  these cells is inhibited by  treatment with 
a VEGFR tyrosine kinase inhibitor [28].  It has also been found that VEGF-A increases 
bone mass through an Flk1 and PI-3 kinase mediated pathway [26]. 
! In our study, we found that addition of a neutralizing antibody specific for Flk1 
(VEGFR2) did not have any  effect on the production of osteocalcin, osteoprotegerin, 
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FGF-2 or Ang-1 in MG63 cells in response to Ti substrate features.  However, VEGF-A 
production in response to treatment with an Flk1 antibody was significantly  increased.  It 
may be possible that VEGF-A interaction with Flk1 in MG63 cells is necessary  for 
maturation of these cells and to overcome the effect of the neutralization antibody, 
production of VEGF-A was increased.
! FGF-2 has also been reported to be a modulator of bone formation in vitro and in 
vivo [42, 43].  In our study, we found that treatment of MG63 cells with 10 ng/mL 
rhFGF-2 increased cell number and alkaline phosphatase specific activity  but had no 
effect on the production of either osteogenic or angiogenic markers.  FGF-2 has also 
been found to induce proliferation of human mesenchymal progenitor cells and MC3T3-
E1 cells [44, 45].  Moreover, treatment of mineralized MC3T3-E1 cultures with FGF-2 
reduced the expression of collagen I, BMP-2, and osteocalcin [44].  In VEGF-A silenced 
cells, addition of rhFGF-2 did not increase cell number to the same extent as seen in 
MG63 wild-type cell cultures, but did increase alkaline phosphatase specific activity 
compared to untreated VEGF-A silenced cells.  However, no increase in the production 
of osteogenic or angiogenic markers by VEGF-A silenced cells were observed in 
response to FGF-2 treatment.  Taken together, these results indicate that VEGF-A, but 
not FGF-2 is necessary for osteoblast differentiation.
! Alkaline phosphatase activity in osteoblast-like cells is highly  dependent on the 
state of maturation of the cells at the time of assay.  In early  osteoblast differentiation, 
alkaline phosophatase activity  increases until the onset of mineralization, at which time 
its activity  decreases, and osteocalcin production is increased [46].  This biphasic curve 
for alkaline phosphatase acitivity  during osteoblast maturation may explain observed 
differences in alkaline phosphatase specific activity  in response to Ti substrate features 
seen in this study compared to other studies.
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! In conclusion, we show here that VEGF-A produced by  osteoblast-like cells in 
response to Ti substrate features has an autocrine effect on the differentiation of these 
cells.  shRNA targeted knockdown of VEGF-A resulted in a reduction in secreted levels 
of osteocalcin, osteoprotegerin, FGF-2, and Ang-1, while treatment with exogenous 
VEGF-A increased secreted levels of these markers.  FGF-2 increased cell number and 
alkaline phosphatase, but had no effect on the production of osteogenic or angiogenic 
markers.  Taken together, these results indicate that VEGF-A, but not FGF-2 plays an 
important role in the differentiation of osteoblasts on Ti substrates.
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Chapter 5:  Hyaluronic Acid Stimulates Neovascularization During the 
Regeneration of Bone Marrow After Ablation
5.1 Introduction
A common objective when using biomedical implants, particularly  in 
musculoskeletal tissues, is rapid apposition of host tissue to the implant surface. 
Currently, several regenerative medicine therapies exist for the restoration and 
augmentation of bone in orthopaedic and dental applications, including autologous and 
allogeneic bone grafts as well as synthetic bone graft substitutes.  While autologous 
bone is still the “gold standard” within the field due to its biocompatibility  as well as its 
source of stem cells and growth factors[1, 2], allografts and synthetic bone substitutes 
also provide an osteoconductive surface to promote bone growth.  A critical requirement 
for the survival of any  bone graft is the rapid ingrowth of blood vessels from the 
surrounding tissue[3].
Hyaluronic acid is a high molecular weight (104 – 107 Da), negatively  charged, 
non-sulfated glycosaminoglycan consisting of repeating units of N-acetylglucosamine 
and D-glucuronic acid[4].  It is a component of the extracellular matrix (ECM) expressed 
in nearly  all tissue types[4] and plays an important role in tissue morphogenesis and 
healing[5, 6].  During wound healing, native hyaluronic acid serves as an anti-angiogenic 
molecule, inhibiting endothelial cell proliferation and migration[7].  These observations 
have lead to the use of the sodium salt of hyaluronic acid (NaHY) in a number of wound 
healing applications[8].  Although NaHY inhibits capillary  formation in a three 
dimensional collagen gel[7, 9], low molecular weight degradation products of NaHY have 
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been demonstrated to stimulate vascular endothelial cell proliferation[10-14], migration
[15], collagen synthesis[16], sprout formation[17], and new blood vessel formation[18].
Allogeneic bone graft substitutes like demineralized bone matrix (DBM) are used 
as filler materials to enhance the healing of fractures and to help regenerate bone in 
osseous defects[19].  Because the particulate, powdery  nature of DBM results in poor 
handling qualities, it is often combined with materials to improve its handling 
characteristics for surgical procedures[19, 20].  Commonly  used materials for this 
process include NaHY, calcium sulfate, glycerol, and gelatin[19].  The combination of 
DBM with these materials creates a more gelatinous substance, allowing for easier 
insertion and molding into osseous defect sites. DBM is known to promote bone 
formation by virtue of its osteoinductive and osteoconductive properties, but whether 
NaHY can also stimulate bone formation when used as a cofactor with DBM is not 
known.  NaHY has also been reported to accelerate bone healing[21].  The exact 
mechanism by  which NaHY promotes bone healing is unknown, but one possibility  is 
that it increases neovascularization in the newly  forming bone. NaHY has already  been 
shown to promote neovascularization in non-bony sites[22] and is being investigated for 
use as a scaffold material for angiogenic tissue engineering[23], supporting this 
hypothesis.
The purpose of the present study  was to determine if NaHY stimulates 
neovascularization during bone formation induced by  DBM.  The study took advantage 
of the rapid endosteal bone formation that occurs following injury to the marrow cavity  of 
rat tibial bone[24].  The rat bone marrow ablation model is an established model for 
examining bone formation and remodeling[25].  It has been well characterized in a 
number of academic laboratories and it is used by  industry  to assess osteogenic 
properties of biomaterials as well as pharmaceuticals[26, 27].  The model is also 
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applicable for assessing endosteal bone formation and remodeling in orthopaedics 
following placement of intramedullary  rods and joint prostheses[28].  In this model, the 
bone marrows of rat tibias are flushed of cells.  A blood clot and granulation tissue fill the 
marrow space over the first three days of healing.  Primary  bone begins to form on the 
endosteal surface by  day  6 and eventually  fills the marrow cavity.  Remodeling of the 
newly  formed bone occurs between days 12 and 25, resulting in resorption of the 
primary  bone.  By  day  35 post-ablation, replacement of the primary  bone with bone 
marrow is complete, resulting in the regeneration of normal tissue phenotype[29].  This 
process follows a well-documented time table[25, 30], which makes it a very  useful 
model for the study  of normal bone repair and for the evaluation of extrinsic and intrinsic 
factors that may  influence it. The enclosed environment of the marrow space restricts 
the distribution of test materials and localizes their effects, thus allowing the model to be 
useful for the study of the effects of biomaterials that have been designed for bone 
augmentation.
In this study, neovascularization occurring within the ablated marrow cavity  was 
assessed over time by  perfusing the vasculature of rats with a radio-opaque silicone 
contrast agent and imaging the vasculature using micro-computed tomography (µCT). 
To determine the role of NaHY in stimulating neovascularization during endosteal bone 
formation, we placed various formulations of NaHY with and without DBM in the ablated 
marrow space of rats.  Vascular morphology of the ablated limbs was assessed 14 days 
post-ablation using both µCT analysis as well as histology.
5.2 Materials & Methods
5.2.1 Materials
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! Implant materials were prepared by  the Musculoskeletal Transplant Foundation 
(MTF, Edison, NJ) and packaged in sterile syringes.  Materials were able to be extruded 
through an 18-gauge needle, which is the largest size able to fit into the hole created for 
the marrow ablation. The DBM used for the study was from a single donor and was 
shown to be osteoinductive in the mouse gastrocnemius muscle pouch assay.  DBM 
particulates ranged in size from 212 to 500 µm in diameter.
5.2.2 Marrow Ablation
! The Institutional Animal Care and Use Committee (IACUC) at the Georgia 
Institute of Technology approved all animal procedures.  Either eight-week or 9-month 
old, male immunocompromised (rNu/rNu) rats were purchased from Harlan Laboratories 
(Harlan, Indianapolis, IN).  Rats were anesthetized with isoflurane gas inhalation, laid on 
their backs and covered with a sterile surgical drape.  The surgical area was shaved and 
disinfected with providone iodine.  An incision was made over the diaphysis of the tibia 
and the surrounding muscles were moved aside using blunt dissection to expose the 
bone.  A round perforation was made in the mid-diaphysis through the cortical bone 
using a 0.9mm round dental bur.  Marrow was excavated with an inverted cone dental 
bur and the marrow space was then flushed with sterile, physiological saline.
! A time course study  was first performed to determine the time at which 
neovascularization was greatest.  The marrow space was left empty, and the covering 
muscles were returned to their normal positions and the skin incision was closed with 
wound clips.  Immediately  after recovery from anesthesia, rats were injected with 
buprenorphine to relieve pain.  Animals had access to food and water ad libitum for the 
duration of the study.  At days 3, 6, 14, 21, and 28 post-ablation, animals (n = 3) were 
perfused-fixed and imaged as described below.  Based on the results of the time course 
study, 14 days post-ablation was selected as the endpoint for the DBM + NaHY study.  
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To examine the role of NaHY in promoting neovascularization during endosteal 
bone formation, we ablated the marrow of eight-week old rat tibias and injected test 
compounds (v  ~ 125 µL) corresponding to the groups outlined in Table 1.  The left hind 
tibias of n = 9 animals were ablated for each group.
5.2.3 Vascular Perfusion
! Following anesthetization, the abdominal cavity  of rats was opened and the 
internal organs were moved aside.  A 22-gauge 1” catheter was inserted into the 
descending aorta and the caudal vena cava was severed to allow for the vasculature to 
be flushed.  250μL of heparin (1000 units/mL) was injected into the catheter to prevent 
clotting of the blood.  The vasculature was flushed with 0.9% normal saline using a 
peristaltic pump set to a flow rate of 15 mL/min. Specimens were subsequently pressure 
fixed with 10% neutral buffered formalin.  Formalin was flushed from the vessels with 
0.9% normal saline, and the vasculature was injected with a radio-opaque silicone 
rubber compound containing lead chromate (Microfil MV-122, Flow  Tech, Inc., Carver, 
MA), according to the manufacturerʼs protocol.  Animals were stored at 4o C overnight to 
allow for contrast agent polymerization.  Rat hind limbs were dissected from the 
specimens and soaked for 4 days in 10%  neutral buffered formalin to ensure complete 
tissue fixation prior to µCT imaging. 
5.2.4 µCT Image Analysis
! Tissue samples were imaged using a high-resolution desktop micro-CT imaging 
system (vivaCT, Scanco Medical, Bassersdorf, Switzerland) as described by  Duvall et al
[31].  Briefly, samples were imaged using a 36 µm voxel size with a voltage of 55 kV and 
a current of 109 µA.  Serial image sections were created in a 1024 x 1024 pixel image 
matrix.  Serial tomograms were reconstructed from raw data using a cone beam filtered 
back-projection algorithm[32].  Noise was reduced using a low pass Gaussian filter 
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(sigma = 1.2, support = 2).  The serial tomograms were globally  thresholded based on x-
ray  attenuation and used to render binarized three dimensional (3D) volume images of 
the repair gap vascular network.  The paramaters for three dimensional vascular 
morphology  (vessel volume, number, connectivity, thickness, and spacing) were 
determined using the method by described in detail by Duvall et al[31] and were 
quantified with histomorphometric analysis based on direct distance transform methods
[33, 34].
5.2.5 Histology
! Following decalcification and µCT imaging, samples were embedded in paraffin, 
and sectioned along the sagittal plane.  5µm sections were stained with haematoxylin 
and eosin (H&E) to assess vascular structures.  The number of blood vessels within the 
ablated marrow  space was counted in four serial sections from each sample and the 
values were averaged to obtain the mean blood vessel number for each treatment 
group.
5.2.6 Statistical Analysis
Both µCT and histology  data from each group were analyzed by ANOVA and 
when statistical differences were detected, Studentʼs t-test for multiple comparisons 
using Bonferroniʼs modification was used.  p-values < 0.05 were considered statistically 
significant.
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Table 5-1.  Demineralized bone matrix and hyaluronic acid experimental group 
formulations
Group # Carrier DBM Comments
A No Carrier No DBM Empty Defect
B Carrier I: 3.8-4.0% solution 
of 700-800kD NaHY in PBS 
buffer pH 7.4
31% Heat denatured DBM
Negative control for test system
C 0.9% Saline 31% No NaHY carrier, DBM baseline
D Carrier I: 3.8-4.0% solution 
of 700-800kD NaHY in PBS 
buffer pH 7.4
31% Represents commercial DBX® putty
E Carrier II: 3.8-4.0% solution 
of 35kD NaHY in PBS buffer 
pH 7.4 
31% Low MW NaHY carrier with 31% 
DBM
F Carrier I 50:50 Carrier II 
mixture
31% Equal mixture of the two carriers with 
31% DBM
G Carrier I: 3.8-4.0% solution 
of 700-800kD NaHY in PBS 
buffer pH 7.4
0% Carrier for commercial DBX putty, no 
DBM
H Carrier II: 3.8-4.0% solution 
of 35kD NaHY in PBS buffer 
pH 7.4 
0% Low MW NaHY carrier only, no DBM
I Carrier I 50:50 Carrier II 
mixture




Ablated, perfused tibias were imaged using µCT to examine the bone (Figure 1A) 
and surrounding vasculature (Figure 1B).  Samples were subsequently  incubated for 72 
hours at 22oC in formic acid (CalEx II, Fisher Scientific, Pittsburgh, PA) to decalcify  the 
bone and facilitate image segmentation of the vasculature both surrounding (Figure 1C) 
and within (Figure 1D) the ablated tibias.  The region of interest (ROI) in 2-D serial 
sections for vascular morphology  analysis was determined by  using the 2-D sections of 
calcified images as a template for the selection of the appropriate area for the ablated 
marrow space.  Assessment of the 3-D vascular morphology  for both the time course 
study  and the NaHY + DBM study  was done using the results based on the images like 
the one shown in figure 1D.
Neovascularization within the marrow cavity  of 8-week old, male athymic rats 
varied as a function of time post-ablation.  Peak blood vessel volume within the marrow 
cavity  was observed on day  14 (Figure 2A) and was significantly higher at this time than 
at all other time points examined (p<0.05).  Similarly, blood vessel connectivity  also 
reached its maximum at day 14 (Figure 2B).  µCT analyses of blood vessel number 
(Figure 2C), vessel thickness (Figure 2D), and vessel spacing (Figure 2E) did not reveal 
any significant differences amongst any  of the time points examined.  However, it should 
be noted that on day  14 post-ablation, a moderate increase in blood vessel number and 
a corresponding in decrease in blood vessel spacing was observed.  The average 
diameter of blood vessels in the marrow remained constant at all time points.  Based on 
these data, it was determined that at 14 days post-ablation, neovascularization occurring 
within the ablated marrow cavity  is at its peak and this time point was selected as the 
endpoint for the NaHY + DBM study.
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Figure 5-1. To demonstrate feasibility  of the procedure, at the time of harvest, rat 
vasculature was perfused-fixed using 10% formalin and a radio-opaque silicone based 
contrast agent (Microfil, Carver, MA).  Ablated, perfused tibias were imaged using µCT to 
examine the bone (Figure 1A) and surrounding vasculature (Figure 1B).  Tissues were 
subsequently  decalcified and imaged with µCT a second time to isolate the vasculature 
both surrounding (Figure 1C) and within (Figure 1D) the ablated tibias.
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Figure 5-2:  Time course of neo-vascularization following tibial marrow ablation.  At days 
3, 6, 14, 21, and 28 post-ablation, rats were perfused-fixed with Microfil (Flow-Tech Inc, 
Carver, MA) and imaged using µCT.  (A) Marrow cavity  vessel volume fraction, (B) 
vessel connectivity, (C) vessel number, (D) vessel thickness, and (E) vessel spacing 
were quantitatively  assessed.  Data are presented as the mean + SEM of three animals 
for each time point. *p< 0.05 vs. all other time points.
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! µCT analysis showed that neovascularization within the marrow cavity  at 14 days 
post-ablation was sensitive to the formulations of NaHY and NaHY + DBM that were 
injected into the marrow space.  DBM alone increased the total blood vessel volume 
fraction in the ablated marrow space compared to heat inactivated DBM (p<0.05) and 
empty defects (not significant).  Addition of low  MW NaHY to DBM further enhanced 
blood vessel volume within ablated marrows compared to empty  defects, heat 
inactivated DBM and DBM alone.  High MW NaHY, low MW NaHY, and high + low MW 
NaHY by  themselves displayed moderate increases in total vessel volume compared to 
empty defects, although none of these were significant (Figure 3A).  Similar to total 
blood vessel volume, the combination of low MW NaHY with DBM increased blood 
vessel connectivity  compared to empty defects, DBM alone and NaHY alone.  High and 
low  MW NaHY decreased blood vessel connectivity  compared to DBM alone (Figure 
3B).  
Three dimensional µCT analysis of vessel number showed that all three 
formulations of NaHY administered either alone or in combination with DBM as well as 
DBM alone increased the total number of blood vessels in ablated marrows compared to 
empty defects and heat inactivated DBM (Figure 3C).  The average vessel diameter in 
the ablated marrow space was found to decrease in low MW NaHY and high + low MW 
NaHY groups compared to empty  defects.  High MW NaHY + DBM showed the lowest 
average vessel diameter amongst all treatment groups (Figure 3D).
When combined with DBM, NaHY also increased the total volume fraction of 
radio-opaque tissue within the marrow cavity  as observed by µCT.  31% DBM by  itself 
did not promote greater bone formation compared to empty  defects, however the 
addition of low MW NaHY to 31% DBM significantly  increased the volume of radio-
opaque tissue within the marrow space compared to DBM alone.  In addition, both high
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Figure 5-3: Influence of DBM and NaHY on neo-vascularization after tibial marrow 
ablation.  14 days after marrow ablation and injection of test compounds, rats were 
perfused-fixed with Microfil and imaged with µCT. (A) Marrow  cavity  vessel volume 
fraction, (B) vessel connectivity, (C) vessel number, and (D) average vessel diameter 
(vessel thickness). Data are presented as the mean + SEM of nine animals per group. 
*p< 0.05 vs. Empty  Defect; #p< 0.05 vs. Inactive + NaHY; $p< 0.05 vs. Active + Saline; 
@p< 0.05 vs. no DBM.
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Figure 5-4:  Marrow cavity  new bone volume.  µCT was used to assess the volume of 
new bone within marrow cavities 14 days after ablation. *p< 0.05 vs. Empty; #p< 0.05 vs. 
Inactive + NaHY; @p< 0.05 vs. no DBM.
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MW NaHY and low  MW NaHY promoted new bone formation to a similar extent as DBM 
alone.  The combination of high + low MW NaHY significantly  reduced the formation of 
new bone compared to empty defects and DBM alone (Figure 4).
To account for the volume occupied by the DBM within the ablated marrow 
cavities on reducing the volume available for neovascularization, we corrected the total 
blood vessel volume fraction in all experimental groups containing DBM.  Based on 
observations from µCT scans, we estimated that DBM occupied approximately  60% of 
the ablated marrow  space.  Figure 4 shows the total blood vessel volume fraction 
adjusted to subtract the volume occupied by  DBM.  The results demonstrate that in both 
the low MW NaHY + DBM and the high + low MW NaHY + DBM groups that when the 
volume occupied by  DBM in the ablated marrows is removed, the blood vessel volume 
fraction is significantly  increased compared to the treatment groups containing either low 
MW NaHY or high + low MW NaHY alone, respectively (Figure 5).
Haematoxylin and eosin stained sagittal sections of the treated tibias showed the 
presence of new bone.  Blood vessel structures containing Microfil were visible in cuts 
from all treatment groups (Figure 6).  Histomorphometric analysis of total marrow cavity 
blood vessel number showed that addition of low MW NaHY significantly  increased the 
number of blood vessels compared to empty defects, heat inactivated DBM, active DBM, 
and a combination of low MW NaHY + 31% DBM (Figure 7).  Addition of both high MW 
NaHY and a combination of high + low MW NaHY increased the number of blood 
vessels in the marrow cavity compared to heat inactivated DBM.
To determine the influence of patient age on the normal healing process, we 
ablated the marrows of 9-month old, male athymic rats and at days 3, 6, 14, 21, and 28 
post-ablation, perfused-fixed the animals and used µCT imaging to assess the three 
dimensional parameters of the vascular network similar to the method used in Figure 2. 
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Assessment of the total vessel volume fraction (Figure 8A), vessel connectivity  (Figure 
8B), vessel number (Figure 8C), vessel thickness (Figure 8D), and vessel spacing 
(Figure 8E) did not reveal any  statistically significant differences amongst any  of the time 
points examined.  However, similar to the results found for 8 week-old animals, there 
was a moderate increase in the total vessel volume fraction and vessel connectivity, with 
a corresponding decrease in the mean vessel spacing distance observed at 14 days 
post-ablation.  The total number of blood vessels and mean vessel thickness did not 
change amongst any of the time points examined.
We also examined new bone formation within the ablated marrows of 9-month 
old rats (Figure 9).  Peak bone volume fraction was observed at 14 days post-ablation, 
although there was no statistically  significant difference in the bone volume fraction 
observed at 14 days post-ablation versus all other time points examined.
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Figure 5-5:  Corrected total blood vessel volume fraction.  µCT total blood vessel 
volume fractions were adjusted to account for the volume occupied by  the DBM within 
the ablated marrow space. Data are presented as the mean + SEM of nine animals per 
group.  *p< 0.05 vs. Empty  Defect; #p< 0.05 vs. Inactive + NaHY; $p< 0.05 vs. Active + 
Saline; @p< 0.05 vs. no DBM.
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Figure 5-6: Representative histological sections of ablated tibias.  Following µCT 
imaging, ablated tibias were embedded in paraffin and processed for histology.  Sections 
were stained with haematoxylin and eosin.  Arrows indicate the presence of vascular 
structures containing Microfil.  Groups analyzed were (A) empty  defect, (B) Inactive + 
NaHY, (C) Active + Saline, (D) High MW NaHY + 31% DBM, (E) Low MW NaHY + 31% 
DBM, (F) High + Low MW NaHY + 31% DBM, (G) High MW NaHY, (H) Low MW NaHY, 
and (I) High + Low MW NaHY.
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Figure 5-7: Effect of tibial marrow ablation on average vessel number within the marrow 
cavity  14-days post-ablation, determined by histomorphometry. *p< 0.05 vs. Empty 
Defect; #p< 0.05 vs. Inactive + NaHY; $p< 0.05 vs. Active + Saline; @p< 0.05 vs. no 
DBM.
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Figure 5-8: Time course of neo-vascularization following tibial marrow ablation in 9-
month old male athymic rats.  At days 3, 6, 14, 21, and 28 post-ablation, rats were 
perfused-fixed with Microfil (Flow-Tech Inc, Carver, MA) and imaged using µCT.  (A) 
Marrow cavity  vessel volume fraction, (B) vessel connectivity, (C) vessel number, (D) 
vessel thickness, and (E) vessel spacing were quantitatively  assessed.  Data are 
presented as the mean + SEM of three animals for each time point. 
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Figure 5-9: Marrow cavity  new bone volume.  µCT was used to assess new bone 
formation within the ablated marrows of 9-month old male athymic rats at days 3, 6, 14, 
21, and 28 post-ablation.
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5.4 Discussion
Successful bone formation surrounding implants is dependent on the 
establishment of a patent vasculature at the bone-implant interface.  This study 
demonstrates that NaHY increases the number of new blood vessels in the ablated 
marrow cavity and suggests that it is also helps to promote osteogenesis.  Both high and 
low  MW NaHY increased the total vessel number compared to empty  defects, with a 
corresponding decrease in average vessel diameter.  Determination of the number of 
vascular structures of mid-sagittal sections supported the µCT observations.  Overall, 
addition of low MW NaHY to DBM resulted in an increase in the total vessel volume 
fraction and vessel connectivity  within ablated marrows.  In addition, a combination of 
low  MW NaHY + DBM resulted in an increase in bone volume fraction compared to 
empty defects, DBM alone, and NaHY alone.  This suggests that low MW NaHY may 
enhance osteogenesis when combined with DBM via increased vascularity  as confirmed 
by greater numbers of smaller vessels.
Bone is a highly  vascularized tissue, and the link between bone formation and 
vascular invasion is well established[35].  Vascularization of cartilage is a prerequisite for 
bone formation during growth and development[36] and the development of a vascular 
bed is necessary  during fracture healing and bone repair and regeneration to allow for 
the migration of osteoprogenitor cells to the healing site as well as to supply  oxygen and 
nutrients and allow for removal of waste[37]. 
DBM is a commonly  used bone graft substitute, due to its osteoconductive and 
osteoinductive properties.  However, VEGF expression and micro-vessel density  (MVD) 
are low during bone healing with DBM compared to autologous bone and synthetic bone 
graft substitutes[3, 38].  When DBM was used in a rat craniotomy defect together with a 
pro-angiogenic compound, both new bone formation and MVD were increased[39].  In a 
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similar manner, hyaluronic acid may  serve to stimulate neovascularization when 
combined with DBM during bone regeneration within ablated marrows of 
immunocompromised rats.
Effects of NaHY on cells have been previously shown to be dependent on the 
chain length of the polymer.  High molecular weight hyaluronic acid serves as a 
structural polymer, sequestering growth factors and other signaling molecules[23].  In 
addition, high molecular weight forms of NaHY inhibit endothelial cell proliferation and 
disrupt endothelial cell monolayers[14].  On the other hand, short, oligomeric fragments 
of NaHY (less than 20 monomers) have been found to be produced at sites of injury  and 
within tumors[13].  The short NaHY fragments bind to cell-surface hyaluronic acid 
receptor proteins such as CD-44, receptor for hyaluronan-mediated motility  (RHAMM), 
and toll-like-receptor-4 (TLR-4)[23].  Activation of these receptors on endothelial cells 
promotes their proliferation and migration, resulting in sprout formation and 
neovascularization[40].  The ability  of NaHY to promote neovascularization has been 
demonstrated both subcutaneously[41] and in a murine epigastric skin flap model[42].
High molecular weight hyaluronic acid is broken down in vivo by  a class of 
enzymes called hyaluronidases[43].  In particular, hyaluronidase-1 (HYAL-1) is 
responsible for the generation of short, pro-angiogenic hyaluronic acid oligomers[18]. 
The generation of these hyaluronic acid oligomers is significantly  increased at sites of 
injury  and inflammation[43, 44].  While no examination of hyaluronidase expression was 
performed in this study, it is possible that following injection of NaHY within the ablated 
marrow, expression of HYAL-1 is increased, resulting in the breakdown of NaHY into 
smaller fragments, which bind to CD-44 receptors present on endothelial cells, 
promoting neovascularization during bone formation.
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! In our model of tibial marrow ablation, we observed that after 14 days, 
DBM particulates were still present within the ablated marrow cavities.  Based on µCT as 
well as histology  observations, we estimated that DBM occupied approximately  60% of 
the total marrow cavity.  This results in a decrease in the total volume available for blood 
vessel invasion.  We have demonstrated in this study  that the enhanced 
neovascularization observed in ablated marrows treated with low MW NaHY + DBM is 
further increased when we account for the volume occupied by the DBM, indicating that 
the neovascularization induced by NaHY is further stimulated by the presence of DBM.
µCT imaging has been shown to be a good model for the three dimensional 
analysis of vascular structures in vivo.  The ability  of µCT to detect smaller vessels and 
capillaries is dependent on the resolution of the imaging system and has been 
investigated previously[45, 46].  In the present study, three dimensional reconstructions 
of the vasculature were generated using a voxel size of 36 µm.  It is possible in our 
model of vascular perfusion that the resolution of the µCT imaging system was unable to 
detect all of the capillaries present in the marrow space, however, a 36 µm voxel size 
has been demonstrated to provide a good analysis of the three dimensional vascular 
network[31].
This study  was designed to limit the number of animals required to meet the 
experimental objectives.  By using µCT and H&E of decalcified tissues to quantify  blood 
vessel number and volume, all measurements could be made on a single set of animals. 
For this reason, only  static histomorphometry  was performed.  We did not do dynamic 
measurements requiring undecalcified sections and fluorochrome labeling.  H&E and 
Microfil were sufficient to identify vascular structures, and for this reason we did not 
perform immunohistochemistry  for endothelial markers like PCAM-1 or von Willebrandʼs 
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factor.  Importantly, the histologic analysis supported the µCT data with regards to blood 
vessel number.
In conclusion, we have shown here that normal bone healing after tibial marrow 
ablation is accompanied by  an increase in neovascularization within the marrow space, 
peaking at 14 days post ablation.  We also show that NaHY stimulates new blood vessel 
formation during new bone formation during healing when used as a carrier for DBM.  In 
particular, low molecular weight (35kDa) NaHY + DBM resulted in increases in total 
blood vessel volume and total bone volume in ablated limbs.  The contribution of the 
vascularization to remodeling isnʼt known.  In an orthotopic site, low  molecular weight 
NaHY might contribute to bone formation by both supporting MSC and progenitor cell 
migration in early  phases of healing and vascular ingrowth as the NaHY is degraded to 
smaller fragments.  However, as a whole, the data suggest that the increase in 
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CHAPTER 6.  Discussion
! The results presented in this thesis demonstrate the important role that 
biomaterial properties have in regulating the angiogenic response of cells in vitro and 
host tissue in vivo.  In particular, the results presented herein show that titanium (Ti) 
surface topography  and surface free energy can affect not only  osteoblastic 
differentiation of cells as has been demonstrated in earlier work, but can also affect the 
production and secretion of pro-angiogenic growth factors that serve both an autocrine 
and paracrine role in osteoblast maturation.  Further, this thesis has demonstrated that 
by  combining osteogenic and angiogenic biomaterials, neovascularization and new bone 
formation can be enhanced during healing.  While these studies have provided insight 
into the role that biomaterial properties have in regulating peri-implant 
neovascularization, there are still several questions to be answered regarding the 
mechanism by  which this process occurs.  Obtaining a greater understanding of how 
biomaterials regulate host cellular and tissue response will allow for the design of 
implants to better promote osseointegration, improving implant success rates and 
implant lifetimes.
6.1 Role of Ti surface features in promoting neovascularization
! The results presented in Chapter 2 of this thesis show that both Ti surface 
roughness and surface free energy  mediate the production of pro-angiogenic growth 
factors by  cells.  Increasing Ti surface roughness resulted in an increase in the 
production of VEGF-A, FGF-2, and EGF by  an MG63 osteoblast-like cell line and an 
increase in the production of VEGF-A by primary human osteoblasts (HOB).  By 
combining surface roughness with a high surface free energy, the production of these 
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pro-angiogenic growth factors by  both MG63 cells and HOBs were further increased.  In 
addition, conditioned media from MG63 cell cultures on SLA and modSLA Ti substrates 
promoted the differentiation of human aortic endothelial cells (HAEC) using an in vitro 
Matrigel® and fibrin gel tubule formation assay  to a greater extent than did conditioned 
media from control TCPS and smooth PT Ti substrates, suggesting that the increase in 
pro-angiogenic growth factor production observed in response to Ti surface 
microtopography and surface free energy  has a paracrine role in the activation and 
differentiation of endothelial cells.
! It should be noted that MG63 cells are a transformed cell line, originally  isolated 
from a 14-year-old Caucasian male with osteosarcoma, and represent an immature 
osteoblast-like phenotype.  It is well established in the literature that cancer cells express 
higher levels of multiple pro-angiogenic growth factors, including VEGF-A, FGF-2, and 
EGF.  This may explain why  secreted levels of FGF-2 and EGF by HOBs were 
undetectable in our ELISA assay systems.  In order to more definitively  show  that Ti 
surface features can promote the production of pro-angiogenic growth factors, further 
characterization using HOBs and other primary  bone cell lines should be done. 
Techniques such as real-time polymerase chain reaction (qPCR) to check for expression 
of pro-angiogenic growth factors or more sensitive ELISA systems could be used to 
achieve this.  Using conditioned media from HOB cell cultures in the in vitro Matrigel® 
and fibrin gel assays, as well as in vivo angiogenesis assays like the chick 
chorioallantoic membrane (CAM) assay or Matrigel® plug assay  could be done to further 
verify  the paracrine effect that the pro-angiogenic growth factors produced by  these cells 
have on endothelial cell response.
! In vivo, it is likely  that the first cells to come into contact with the implant surface 
are mesenchymal progenitor cells that differentiate down an osteoblast lineage.  Earlier 
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studies from our laboratory have found that Ti surface features have the ability  to induce 
osteoblastic differentiation of human MSCs without the addition of exogenous growth 
factors or chemicals.  The effect that Ti surface properties have on the ability  to regulate 
the production of pro-angiogenic growth factors in MSCs during osteoblastic 
differentiation should be more fully characterized.
! Our results from Chapter 2 of this thesis also established that Ti implant surface 
characteristics have an effect on both bone formation and new blood vessel formation in 
vivo.  Using a novel, murine intramedullary  femoral press-fit model, we observed an 
increase in both bone-to-implant-contact and new blood vessel formation in aged mice, 
though in young, healthy  mice, no differences in bone-to-implant contact were observed. 
In this thesis, we harvested implants after either 28 or 35 days for analysis.  It would be 
useful to perform a time course study  in mice to look at the development of new 
vasculature and new bone over time.  Additional techniques, such as µCT analysis of the 
three dimensional vascular network and mechanical testing could be also be done to 
provide a more in depth analysis of the effect that Ti surface features have on bone 
formation in vivo.  Taking advantage of the numerous transgenic mice that have been 
developed, this model could be used to look at the roles of specific growth factors 
involved in osteogenesis and angiogenesis in vivo.
6.2 Integrin signaling in angiogenic growth factor production
! Integrins are a family  of heterodimeric cell adhesion molecules that play 
an important role in cellular processes in multiple tissue types in the body.  Signaling 
through integrin receptor complexes is known to initiate intracellular signaling cascades 
that control cellular proliferation and differentiation.  The results presented in Chapter 3 
of this thesis found that the production of pro-angiogenic growth factors by osteoblast-
like cells is at least partially  regulated through specific integrin receptor signaling.  Using 
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shRNA techniques, we stably  silenced MG63 human osteoblast-like cells for integrin 
subunits α1, α2, α5, and β1.  Our results found that the production of the pro-angiogenic 
growth factors VEGF-A, FGF-2, and Ang-1 were affected by knockdown of these integrin 
subunits. In particular, secreted levels of VEGF-A were increased in cells silenced for 
integrins α2, α5, and β1 whereas silencing of integrin α1 resulted in a decrease in VEGF-
A production in response to Ti surface topography  and energy.  Levels of FGF-2 were 
only  affected in response to knockdown of either α1 or α2, and were decreased on 
modSLA Ti surfaces in these cells.  In contrast, secretion of Ang-1 was increased on 
modSLA Ti surfaces in α1, α2, and β1 silenced cells compared to wild-type MG63 cells. 
Taken together, these results suggest that signaling events through integrin adhesion 
receptors may  regulate the production of pro-angiogenic growth factors to induce 
endothelial cell migration and subsequent vascular formation during peri-implant healing.
! Earlier studies showed that the α2 and β1 integrin subunits are particularly 
important in mediating the differentiation of osteoblasts in response to Ti surface 
features. Knockdown of either the α2 or β1 integrin subunits in MG63 cells blocks surface 
roughness dependent differentiation of those cells. In these studies as well as our results 
presented here, only  one integrin α or β subunit is examined.  In vivo, multiple integrin 
receptors are expressed and involved in cell interaction with the extracellular matrix. 
Thus, it is possible that other integrin receptor pairs may  be involved in the angiogenic 
response cells to the implant surface, including αvβ3, α3β1, αvβ5, or others.  In order to 
more fully  elucidate the role that integrin signaling has in cell response to implant 
surfaces, knockdown of other α and β subunits should be done.
! It is also possible that other mechanisms are involved in the production of 
angiogenic growth factors by these cells.   Tissue hypoxia is one of the most well known 
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initiators of neovascularization within the body.  The hypoxia inducible factor pathway  is 
activated in response to hypoxia. Under conditions of normal oxygen tension, HIF-1α 
subunits are hydroxylated and marked for degradation by  the proteosome by  the von 
Hippel-Lindau (VHL) tumor suppressor protein.  However, when oxygen concentrations 
drop below approximately  5%, HIF-1α accumulates in the cytoplasm and translocates to 
the nucleus, where it interacts with the constitutively expressed HIF-1β subunit to 
activate gene transcription.  Several genes associated with angiogenesis are either 
directly  or indirectly  affected in response to hypoxia, including vascular endothelial 
growth factor and its receptors, fibroblast growth factors, and angiopoietins.  When 
implants are inserted into the body in vivo, it is likely  that hypoxia plays a major role in 
the angiogenic response.  In our studies in vitro however, the hypoxia inducible factor 
pathway is not likely  to be activated, indicating that other mechanisms, such as integrin 
receptor signaling or growth factor signaling may  be regulating the production of pro-
angiogenic growth factors.  
6.3 Role of VEGF-A
! VEGF-A is widely  recognized as the most potent endothelial cell mitogen and is 
one of the primary  growth factors involved in the initiation of angiogenesis.  Bone is a 
highly  vascularized tissue and osteoblasts and osteoblast progenitor cells are known to 
produce and secrete VEGF-A and express the VEGF receptors, VEGFR1 (Flt1) and 
VEGFR2 (Flk1/KDR).  In Chapter 4, we found that VEGF-A has both an autocrine and 
paracrine role in osteoblast-like cell differentiation in response to Ti surface 
microtopography and surface free energy.  shRNA silencing of the VEGF-A gene in 
human MG63 cells resulted in a decrease in the production of osteocalcin, 
osteoprotegerin, VEGF-A, FGF-2, and Ang-1 by  these cells in response to Ti surface 
features, suggesting that interaction of VEGF-A with its receptors present on these cells 
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at least partially  mediates MG63 cell differentiation.  Additionally, conditioned media from 
VEGF-A silenced cell cultures failed to stimulate endothelial cell tubule formation to the 
same extent as media from wild-type cell cultures, indicating that VEGF-A produced by 
these cells has a paracrine role in mediating endothelial cell differentation.  
! While inhibition of endogenous VEGF-A by  MG63 cells inhibited the 
differentiation of these cells, blocking VEGF-A interaction with the Flk1 receptor did not 
effect MG63 cell differentiation, though production of VEGF-A was significantly 
increased, possibly  as a response to overcome the effect of the Flk1 neutralization 
antibody.  Further, addition of exogenous VEGF-A to MG63 cell cultures increased the 
production of osteocalcin, osteprotegerin, FGF-2, and Ang-1 by  these cells in response 
to Ti substrate roughness and surface free energy.  
! While the results presented in this thesis illustrate the important role that VEGF-A 
has in osteoblast-like cell differentiation, it raises further questions about the interaction 
of growth factors with their receptors during osteoblast differentiation.  It is possible that 
VEGF-A is acting through VEGFR1, neuropilins, or another receptor in our system and 
further studies should be done to determine what receptor for VEGF-A is the primary 
mediator of osteoblast cell response.  The effect of VEGF-A on osteoblast differentiation 
in response to Ti surface features should also been done using HOBs since the 
expression of VEGF-A and its receptors may be dysregulated in MG63 cells.  Also, what 
effect VEGF-A has on the differentiation of MSCs in response to Ti surfaces would also 
be interesting to examine.  
! The interaction between VEGF-A and other growth factors during osteoblast 
differentiation should also be examined.  Osteoblasts express receptors for numerous 
growth factors, including BMP-2, TGFβ, FGFs, and Ang-1.  The spatio-temporal 
expression of these growth factors and their receptors during osteoblast differentiation in 
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response to Ti surface features would aid in our general understanding of osteoblast 
interaction with implant surfaces.
6.4 Neovascularization in vivo
! In Chapter 5 of this thesis, we found that a combination of demineralized bone 
matrix (DBM) with low molecular weight sodium hyaluronate (NaHY) improved both new 
bone formation and neovascularization in vivo using the marrow ablation model.  Three 
dimensional micro-computed tomography  (µCT) analysis showed that the total bone 
volume fraction as well as several vascular network parameters, including vessel volume 
fraction, vessel number, and vessel connectivity  within ablated limbs were increased 
over empty  defect controls at 14-days post-ablation.  These results suggest that by 
combining an osteogenic stimulus with an angiogenic stimulus, new bone formation may 
be enhanced via increased vascularity.  This data represents a good first step in 
designing combination materials for use in bone regeneration.  
! In the marrow ablation model, the marrow space is filled with new bone that is 
subsequently  remodeled to restore normal tissue phenotype.  This process is well 
documented and occurs during normal healing without any intervention.  In order to 
more fully  determine if a combination of NaHY and DBM can lead to greater bone 
formation at a faster rate, it would be useful to use an injury  model such as a segmental 
or critical sized defect, where complete healing will not occur without intervention.  It 
would also be interesting to see how NaHY and DBM are exerting their effects on cells in 
vivo through examination of receptors present on osteoblast and endothelial cells as well 
as their progenitors, and the expression of different growth factors in the regenerating 
tissue.
! Our results presented in Chapter 5 also found that there appeared to be no 
difference in the normal healing response after marrow ablation between young (8 week) 
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and old (9 month) rats.  Data in the literature suggests that healing ability  after injury  in 
older populations is reduced and that the healing process occurs over a longer period of 
time after injury.  In our study, we examined both neovascularization and new bone 
formation at 3, 6, 14, 21, and 28 days post-ablation.  In both young and old animals, we 
observed peak neovascularization and peak new bone at 14 days post ablation.  It is 
possible that in young animals, neovascularization and bone formation peak somewhere 
between 6 and 14 days post-ablation and that the results we observed for 
neovascularization and bone formation were declining at the 14 day  time point.  A more 
detailed anlaysis should be done that incorporates more time points between 6 and 14 
days to confirm this.
6.5 Conclusions
! This thesis has demonstrated that biomaterial properties are important in 
determining host cellular and tissue response with regards to the production of pro-
angiogenic growth factors during osseointegration.  However, more work remains to fully 
understand the mechanism of interaction between cells and a biomaterial surface.  A 
more detailed examination using the studies outlined in the above sections of this 
chapter will help in understanding this process.  In addition to the role that biomaterial 
properties have in promoting osteogenesis and angiogenesis at the bone/implant 
interface, two other cell types that play  an important role in the early  healing events after 
implant implantation are inflammatory cells and nerve cells.  Other work in our lab has 
shown that modSLA Ti substrates may  reduce the inflammatory  response.  In addition to 
mineralized tissue and blood vessels, bone is a highly  innervated tissue and the ability  of 
implant materials to promote not only  osteogenesis and angiogenesis but new nerve 
growth is essential for the design of next generation biomaterials.  The results presented 
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here provide more fundamental insight into the interaction between cells and 
biomaterials and will ultimately aid in the better design and evaluation of biomaterials.
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APPENDIX
Figure A-1.  Scanning electron micrographs of (A) PT and (B) SLA Ti surfaces.
Ti Surface Characterization
Table A-1: Characterization of surface roughness.  Sa, arithmetic mean deviation of the 
surface; Sq, root-mean-square deviation of the surface; St, maximum peak-to-valley 
height of the surface; Sk, amplitude distribution skew.  Values are means + SEM of 10 
independent cultures.  *p<0.05, v. SLA and modSLA.
Roughness Parameter (μm) SLA ModSLA PT
Sa        1.2 ± 0.04        1.2 ± 0.03        0.6 ± 0.1*
Sq        1.5 ± 0.05        1.5 ± 0.03        0.7 ± 0.1*
St        7.9 ± 0.5        7.8 ± 0.3        3.9 ± 0.6*
Sk        4.5 ± 2.3        4.6 ± 2.2        1.8 ± 0.5
Table A-2: Characterization of surface chemical composition.  Surface chemical 
composition was measured by X-ray  photoelectron spectroscopy.  Values are means + 
SEM of 10 independent cultures.  *p<0.05, v. SLA and modSLA; †p<0.05, v. SLA; 
‡p<0.05 v. mod SLA.
Chemistry Composition (%) SLA modSLA PT
O 50.2 ± 2.6 60.1 ± 0.7† 47.6 ± 1.2‡
Ti 14.3 ± 1.4 23.0 ± 1.1† 17.9 ± 1.0*
N   1.3 ± 0.3   0.7 ± 0.2† 1.2 ± 0.4
C 34.2 ± 2.0 14.9 ± 0.9† 29.2 ± 1.5*
159
Total Vessel Volume Fraction for Ablated and Contralateral Control Limbs
Figure A-2. Vessel volume fraction for ablated and contralateral control limbs.  µCT 
analysis was used to quantify  both the total and bone marrow blood vessel volume 
fractions for ablated and contralateral control limbs for the following treatment groups: 
700-800 kDA NaHY + 31%  DBM, 35 kDa NaHY + 31%  DBM and 700-800 kDa NaHY 
50:50 35 kDa NaHY + 31% DBM.  Results show that ablation and subsequent treatment 
did not elicit a systemic effect on neovascularization.
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Figure A-3. Vessel volume fraction for ablated and contralateral control limbs.  µCT 
analysis was used to quantify  both the total and bone marrow blood vessel volume 
fractions for ablated and contralateral control limbs for the following treatment groups: 
700-800 kDA NaHY + 0%  DBM, 35 kDa NaHY + 0% DBM and 700-800 kDa NaHY 50:50 
35 kDa NaHY + 0% DBM.  Results show that ablation and subsequent treatment did not 
elicit a systemic effect on neovascularization.
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Figure A-4. Vessel volume fraction for ablated and contralateral control limbs.  µCT 
analysis was used to quantify  both the total and bone marrow blood vessel volume 
fractions for ablated and contralateral control limbs for the following treatment groups: 
0.9% Saline + 31%  DBM, 700-800 kDa NaHY + 31% Heat Inactivated DBM and Empty 
Defect.  Results show that ablation and subsequent treatment did not elicit a systemic 
effect on neovascularization.
